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Abstract

MEDICATION-RELATED PROBLEMS IN OLDER ADULTS: A FOCUS ON
UNDERUSE OF WARFARIN AND WARFARIN-ANTIBIOTIC INTERACTIONS
By Parinaz K. Ghaswalla, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2011
Major Advisor: Dr. Patricia W. Slattum, Pharm.D., Ph.D.
Director, Geriatric Pharmacotherapy Program
Associate Professor, Department of Pharmacotherapy and Outcomes Science

The work presented in this dissertation focuses on two important medicationrelated problems in older adults, that is, untreated indication and drug-drug interactions,
specifically with respect to a high-risk medication such as warfarin. Warfarin is a
challenge to use in clinical practice due to its narrow therapeutic index, variability in
dose-response and its interactions with numerous foods and drugs. This dissertation
presents the research from two projects. In the first project the prevalence and predictors
of warfarin use in nursing home (NH) residents with atrial fibrillation (AF), and use of
secondary stroke prevention strategies was determined, in order to understand the
patterns of anticoagulant use in frail NH residents and to identify patient characteristics
associated with warfarin use. In the second project the effect of oral antibiotics on
anticoagulation outcomes, when prescribed concomitantly with warfarin, was
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determined, in order to provide evidence on the clinical significance of warfarinantibiotic interactions in older adults.
In the first project a cross-sectional analysis of the prescription and resident files
from the 2004 National Nursing Home Survey was done to determine the prevalence of
AF and rates of use of warfarin and other anti-platelet agents, such as aspirin and
clopidogrel. A multiple logistic regression model was used to determine factors
associated with warfarin use. In this sample of older NH residents, 13% of residents had a
diagnosis of AF, with indications for warfarin use and no contraindications to warfarin.
From these patients, 30% received anticoagulant therapy with warfarin and 23% of the
remaining patients received either aspirin or clopidogrel, suggesting that more than 50%
of residents with AF did not receive any form of anticoagulant therapy. Non-white race,
history of bleeding, and use of anti-platelet medications were associated with reduced
odds of receiving warfarin.
The second project was a retrospective medical record review of older patients
from an outpatient anticoagulation clinic at a Veterans Affairs medical center. Results of
the repeated measures ANOVA suggested a significant increase in post-antibiotic INR
values with fluoroquinolones, azithromycin and amoxicillin. In addition, the percentage
of patients with warfarin dose adjustments was significantly greater with
fluoroquinolones and azithromycin as compared to cephalexin. No bleeding events were
reported for any of these patients.
In conclusion, the results of the projects suggest that there is underuse of warfarin
in NH settings. Furthermore, antibiotics may be safely prescribed with warfarin in older
adults as long as the INR is monitored closely.
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CHAPTER 1
Introduction
I. Medication-Related Problems in Older Adults
Older adults are the largest consumers of medications, such that more than half the
community-dwelling older adults in the US are prescribed 5 or more medications, overthe-counter medications or dietary supplements.(1) Nursing home residents are
prescribed an average of 7-8 medications.(2) Due to this high use of medications, older
adults have the greatest risk of a medication-related problem (MRP).(1) A medicationrelated problem may be defined as “an event or situation involving drug therapy that
negatively interferes with a patient’s health”.(3) The average number of MRPs in older
adults ranges from 2 to 3,(4) and these are generally more severe in older adults.(5)
Aging increases the risk for MRPs since older adults become more sensitive to
medications and may experience adverse drug reactions or increased side effects for
several reasons. These reasons include- increased risk of chronic illnesses during which
the body may metabolize or respond to drugs differently, multiple medications, complex
dosing schedules, age-related physiological changes and higher likelihood of receiving
un-coordinated care.(6) The high healthcare cost associated with MRPs may represent a
serious economic problem. It has been estimated that for every dollar spent on drugs in
nursing facilities, $1.33 in healthcare resources are consumed in the treatment of
medication-related morbidity and mortality.(7) The total cost of MRPs is approximately
$85 billion annually.(5) MRPs are commonly classified into eight general categories as
shown in table 1.(3)
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The research presented in this dissertation mainly focuses on two MRPs in older adults,
i.e. untreated indication and drug-drug interactions, and specifically related to the highrisk drug warfarin. Rates of untreated indication or underuse of beneficial medications in
older adults have been reported to be present in around 62-64% of older adults.(8, 9)
Similarly, drug-drug interactions are highly prevalent in older adults, such that
approximately 2.2 million older adults were found to be at a risk of a major potential
drug-drug interaction in a national cross-sectional study.(1) Nearly, half of these involved
the use of warfarin or the anti-platelet agent, aspirin.

Interestingly, many MRPs are believed to be predictable and therefore preventable. In a
study that assessed the incidence and preventability of adverse drug events in ambulatory
patients aged 65 years and above, of the 1523 adverse drug events that were reported,
27.6% (421) were judged preventable.(10) On December 9, 2008, the American Society
of Consultant Pharmacists (ASCP) submitted a written report to the transition team of
then President-Elect Barack Obama, to highlight the issues surrounding MRPs in older
adults along with some suggestions for reducing the prevalence of these problems.(11)
Thus this health care issue has received national importance. Furthermore, by 2030 the
population of Americans aged 65 years or older is expected to double, given the longer
life expectancy and aging baby boomers.(12) Thus MRPs in the aging population may
have an even greater impact on health care costs as the population is expected to reach 71
million by 2030, which would roughly represent 20% of the US population.
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Table 1: Categories of medication-related problems in older adults (3)
Type of MRP

Definition

1. Untreated Indication

Patient requires drug therapy but is not receiving medication
for that indication
Patient requires drug therapy but is taking the wrong
medication
Patient is being treated with an inadequate dose of the correct
medication
Patient has a medical problem that is the result of not receiving
a drug
Patient is being treated with too much of the correct drug
Patient has medical problem that is the result of an unintended
and detrimental adverse drug effect
Patient has medical problem that is the result of a drug-drug,
drug-food, or drug-laboratory interaction
Patient is taking a drug without a valid medical reason

2. Improper Drug
Selection
3. Subtherapeutic
Dosage
4. Failure to Receive
Drugs
5. Overdosage
6. Inverse Drug
Reaction
7. Drug Interaction
8. Drug Use Without
Indication

II. Use of High-Risk Medications in Older Adults
Although warfarin is a frequently prescribed medication in the older population, it is also
considered to be a high-risk medication.(13) Warfarin has been included in the list of
high-alert medications developed by the Institute for Safe Medication Practices
(ISMP).(14) This list was developed based on error reports submitted to ISMP’s national
reporting program, harmful error reports from the literature and inputs from practitioners
and safety experts. An increased risk of adverse events due to warfarin has also been
supported by previous research. National estimates of emergency department (ED) visits
among US patients aged 65 years and older found that of 177,504 ED visits for adverse
drug events in 2004-2005, only 3.6% of them visits were for medications considered to
be potentially inappropriate according to the Beers criteria.(15) Instead 33% of visits
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were due to adverse events from 3 other medications, i.e. warfarin (17.3%), insulin
(13.0%) and digoxin (3.2%). However, warfarin, insulin and digoxin are critical
medications that should not be labeled as ‘inappropriate’ due to the high rates of ED
visits. Instead, greater efforts may be required for improving the quality of prescribing
and monitoring for patients on these high-risk medications. According to Budnitz et al,
“because of the high risk for adverse events and the common outpatient use of warfarin,
insulin and digoxin, even small improvements in the use of these medications may have
greater potential for reducing the burden of serious adverse drug events among older
Americans, as measured by ED visits, than do large reductions in the prescription of
lower-risk medications, such as those considered to be potentially inappropriate by the
Beers criteria.”(15) Furthermore, warfarin is prescribed frequently for older adults. In a
cross-sectional, nationally representative probability sample of community-residing
individuals aged 57-85 years, it was found that cardiovascular agents were the most
commonly used class of prescription medications and this included anticoagulants such
as warfarin.(1)

A. Warfarin Pharmacotherapy
Anticoagulation therapy with coumarins or vitamin K antagonists, such as warfarin, is
recommended for the prevention and treatment of thromboembolic complications in
patients with atrial fibrillation (AF), venous thromboembolism (VTE), and acute
coronary syndromes and after invasive cardiac procedures.(16-18) It exhibits its
anticoagulant effect by interfering with the γ-carboxylation of vitamin-K dependent
coagulation factors II, VII, IX, and X, by preventing the cyclic interconversion of vitamin
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K and its 2,3 epoxide (vitamin K epoxide), as shown in figure 1.(19) Warfarin is a
racemic mixture of two optically active isomers, the R and S enantiomers, from which Swarfarin is 2.7-3.8 times more potent than R-warfarin and is metabolized by the CYP2C9
enzyme, whereas R-warfarin is metabolized by CYP1A2 and 3A4.(19) Warfarin is
highly-water soluble and reaches maximal blood concentrations about 90 minutes after
oral administration due to its high bioavailability.(19)

Although warfarin has been the mainstay of oral anticoagulant therapy for over 60 years,
it remains a challenge to use in clinical practice since several factors may complicate
warfarin therapy. It is a drug with a narrow therapeutic index and exhibits considerable
variability in dose response; thus, maintaining therapeutic levels of warfarin is
challenging.(19) It is due to these reasons that patients taking warfarin are required to
have their international normalized ratio (INR) monitored frequently. INR is a standard
used for assessing the clotting tendency of blood in patients receiving anticoagulant
therapy. The recommended INR monitoring period is every 4 weeks; however, this may
change depending on patient-related factors, number of medications or when changes are
made to the patient’s diet or drug regimen.(19) According to the American Geriatrics
Society (AGS) guidelines for use of warfarin in older adults, the recommended INR
range is 2.0-3.0 for prevention and treatment of venous thrombosis and
thromboembolism, prevention of stroke in patients with non-valvular atrial fibrillation
and/or acute myocardial infarction, and in patients with valvular heart disease.(20) The
target INR range may be higher in patients who suffer recurrent systemic embolism
despite adequate oral anticoagulant therapy (2.5-3.5; target INR=3.0).
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Figure 1: Mechanism by which warfarin inhibits the vitamin-K dependent synthesis
of biologically active forms of essential clotting factors, II, VII, IX and X.(19)

(Figure excerpted from Ansell J, et al. Chest 2008; 133 (6 Suppl):160S-98S)

B. Warfarin-Related Adverse Anticoagulation Outcomes
The most common adverse outcome caused by warfarin is a bleeding event. The rates of
fatal or major bleeding have been determined to be about 1.35 per 100 patient years, and
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the rates of intracranial hemorrhage (ICH) was 0.4 per 100 patient-years.(21) Rates of
major hemorrhage in patients treated with warfarin in routine clinical practice have been
reported to range from 1.7-3.4%.(21) Some factors that directly govern the risk of a
bleeding event during warfarin therapy include, the intensity of anticoagulation, patient
characteristics such as age, concomitant use of drugs that may interfere with hemostasis
and the length of therapy.(21) As shown in figure 2, the ‘ideal’ balance between
prevention of ischemic stroke and avoidance of hemorrhagic complication is achieved at
an INR from 2.0-3.0. According to the results of a meta-analysis, the risk for hemorrhage
and thromboemboli was minimized when the patients’ INR remained within 2.0-3.0,
whereas, the risk of bleeding increased significantly for INR values within 5.0-9.0.(22) It
is well established that the risk of hemorrhage is the highest during the first 3 months of
warfarin therapy.(23)

The definition of a bleeding outcome may vary across studies. Some studies define
bleeding as being minor, major or life threatening. Minor bleeds are those that are
generally reported to the physician, but do not require additional testing, referrals or
visits. Bleeding may be defined as major if it is intracranial or retroperitoneal, if it
directly leads to death or if it results in hospitalization or transfusion.(21) Major bleeding
may also be defined as life threatening bleeding in some cases. Although very rare,
intracranial hemorrhage is the most feared complication during warfarin therapy, since
most patients do not completely recover. Several different strategies are available for the
management of supratherapeutic INR, i.e. INR > 4.0, or a bleeding event. Depending
upon the INR or severity of the bleed, warfarin dose may either be lowered or omitted.

	
  

7	
  

The patient may be administered vitamin K or more than one warfarin dose may be
withheld. In the case of significant bleeding, the patient may be given a vitamin K
infusion, supplemented with fresh frozen plasma, prothrombin complex concentrate or
recombinant factor VIIa.(19, 24)

An association of increasing age with increased risk of serious bleeding has been
demonstrated in a recent meta-analysis (adjusted hazard ratio per decade increase, 1.16;
95% CI, 1.47-1.77).(25) Since hemorrhagic events are the major complications of
warfarin therapy, such events may limit warfarin use in older adults, especially frail older
adults.(21, 23) Under-treatment of high-risk atrial fibrillation patients with warfarin
therapy in clinical practice has been reported consistently in the past across all patient
populations.(26) It is possible that the rates of under-treatment with warfarin may be even
higher for older adults, especially for frail nursing home residents with atrial fibrillation,
for whom the fear of bleeding events may be higher. Fear of bleeding complications is
often cited as the reason for not adequately prescribing warfarin and the perception of
stroke and bleeding risk has shown considerable variation among physicians.(27)
Physicians are often more likely to overestimate the reported risks of major bleeds with
warfarin, which may further result in under-treatment with anticoagulant therapy for
patients with atrial fibrillation.(28) Due to this possible association between fear of
bleeding complications in older adults and under-treatment with warfarin, it is important
to determine the rates of warfarin use in older adults, especially frail nursing home
residents in whom anticoagulation rates may not have been adequately studied
previously.
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Figure 2: Adjusted odds ratio for ischemic stroke and intracranial bleeding in
relation to intensity of anticoagulation as measured by the international normalized
ratio (16)

(Figure excerpted from Fuster V, et al. Europace. 2006; 8(9):651-745)

C. Warfarin-Drug Interactions
ASCP includes drug-drug interactions as one of the top 5 medication-related problems
commonly seen in older adults. (29) Many medications undergo pharmacokinetic or
pharmacodynamic interactions with warfarin,(30) and warfarin-drug interactions have
been ranked at number 3 in the list of top 30 adverse events reported for warfarin in the
FDA’s Adverse Events Reporting system for the period from June 2003 to July 2006.(31)
These top 30 adverse events were either indicative of, or associated with bleeding events.
In addition, out of the top 10 dangerous drug interactions in nursing home residents, 5 of
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the interactions involve warfarin, and 3 of these involve warfarin-antibiotic combinations.
The second, third and fourth most dangerous drug interactions on this list involve
warfarin with sulfa drugs, macrolides and fluoroquinolones respectively. This list was
developed as one of the initiatives of the Multidisciplinary Medication Management
Program.(32) Furthermore, the most recent systematic review on warfarin-drug
interactions, recommends exercising caution while prescribing antibiotics to warfarin
patients, since they may cause a change in the patient’s hematological response to
warfarin.(30) Among the various antibiotic classes, fluoroquinolones, macrolides,
tetracyclines and penicillins have been listed in the review article.

Studies have shown that warfarin and antibiotics are commonly co-prescribed in older
adults. For example, in a study of 256 patients discharged on warfarin, 54% received a
potentially interacting medication, from which 67% of the prescriptions were for
potentially interacting antibiotics.(33) In another study done in the Netherlands, almost
39% of all users of coumarin anticoagulants were co-prescribed an anti-bacterial drug
that was considered to be potentially interacting with warfarin.(34) Potential warfarin
interacting antibacterial agents, such as sulphonamides, quinolones and macrolides, were
also found to be the most widely co-prescribed class of drugs with warfarin, in a study
done in Scotland.(35) An interesting finding of this study was that the rate of prescribing
of macrolides in warfarin patients was lower than the rate for non-warfarin patients. This
may suggest an increased awareness among physicians regarding the risk of this potential
interaction. However, no study done in the United States has shown this difference in
prescribing patterns between users and non-users of warfarin. Adverse outcomes
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associated with warfarin use have also been demonstrated previously. Of all the patients
that were admitted to an emergency department, 11% were admitted due to a warfarin
drug interaction.(36, 37) Antibiotics also led to over-anticoagulation in hospitalized
patients receiving oral anticoagulants, such that 8 of the 13 patients that experienced an
increase in INR>5.0 had recently started therapy with antibiotics, antifungals or
amiodarone.(38) Fluoroquinolones are a widely used class of antibiotics. A study that
assessed the trends of antibacterial use in the United States from 2002 to 2006 concluded
that out of all classes of antibiotics, fluoroquinolones were the most commonly used.(39)
However, the clinical significance of warfarin-fluoroquinolone interactions is not
clear,(40) suggesting that there is a need for further research on warfarin-antibiotic
interactions.
D. Summary
This chapter gave an overview of medication-related problems in older adults with a
focus on two types of MRPs, that is, untreated indication and drug-drug interactions.
Certain issues with the use of warfarin therapy in older adults were also highlighted. The
next chapter provides a detailed literature review of underuse of warfarin in nursing home
settings and the available clinical evidence for warfarin-antibiotic interactions. It also
provides a literature review of the effect of age on warfarin-fluoroquinolone interactions.
The next section will provide some gaps in the literature as they relate to underuse of
warfarin and warfarin-antibiotic interactions in older adults and the significance of
conducting this research.
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CHAPTER 2
Literature Review

I.

Warfarin Use in Nursing Home Residents

The purpose of this section is to review the available literature to determine the
prevalence of warfarin use in nursing home (NH) residents. This would help to develop a
better understanding of the use of this ‘high-risk’ medication in NH residents who
generally tend to be frailer than community-dwelling older adults and are using multiple
medications for multiple co-morbid conditions. The literature was also searched to
identify the factors associated with use of warfarin in NH residents.

A. Review of the Literature:
Overall three studies have determined the prevalence of warfarin use specifically in NH
residents. In the study by McCormick et al., the medical records of all residents from a
convenience sample of 21 community-based long-term care facilities were reviewed to
determine whether they had a diagnosis for atrial fibrillation (AF).(1) From a total of
2587 records, 429 (17%) residents had a diagnosis for AF. Of these 429 patients with AF,
180 (42%) were prescribed warfarin and from the 83 ‘ideal’ candidates with AF and no
contraindications to warfarin use, only 44 (53%) received warfarin. Similarly, in another
study the medical records of patients residing in 30 long-term care facilities were
reviewed to determine the prevalence of AF and the proportion of patients receiving
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anticoagulation therapy.(2) A total of 5500 residents were studied from which 413 (7.5%)
were residents with a diagnosis for AF. Of these 413 subjects with AF, 130 (32%)
received a treatment with warfarin. One of the earliest studies to have documented an
underuse of warfarin in nursing home residents showed that only 17 (20%) of 85 patients
with AF received anticoagulation therapy with warfarin.(3) A summary of these studies
has been presented in table 1. Furthermore, a recent study evaluated the treatments
received by patients for stroke prevention using data from the Minimum Data Set
(MDS).(4) From a total of 14,469 patients identified with a previous stroke event, 48%
received warfarin or any kind of antiplatelet medication such as clopidogrel, aspirin,
ticlopidine or dipyridamole. The biggest limitation of this study is that MDS does not
differentiate between ischemic and hemorrhagic stroke. Since anticoagulant or
antiplatelet therapy is not recommended for patients who have had a hemorrhagic stroke,
the rates of underuse may have been over-estimated. Thus while determining the
prevalence of warfarin use in patients with AF, it is beneficial to identify a group of
patients with AF who do not have any contraindications to anticoagulant or antiplatelet
therapy.
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Table 1: Summary of studies documenting underuse of warfarin in
nursing home residents with atrial fibrillation
Reference

Study
Setting

Total no. of
Residents
(N)

N (%) of
Residents
with AF

N (%)
Treated
with
Warfarin

Factors
Associated with
Warfarin Use

McCormick
(2001)(1)

21 LTC
facilities

2587

429 (17%)

180 (42%)

Number of
bleeding risk
factors

Gurwitz
(1997)(2)

30 LTC
facilities

5500

413 (7.5%)

130 (32%)

Age ≥ 85 years,
history of stroke,
diagnosis of
dementia

Lackner
(1995)(3)

5
Nursing
Homes

902

85 (9.4%)

17 (20%)

-

LTC = Long-term care

B. Significance
Based on a review of the literature, studies have consistently reported an underuse of
warfarin in long-term care facilities with the rates of underuse ranging from 50-70%.
However, most of these studies were done more than 10 years ago. Newer anti-platelet
medications, such as clopidogrel have become available for secondary stroke prevention
and are increasingly being used for patients in whom warfarin is contraindicated. Other
antiplatelet medications such as ticlopidine are not recommended for use in older adults
anymore. While previous studies have included a sample of residents from many longterm care facilities, none of them included a nationally representative sample of longterm care residents. An estimation of national rates of NH residents with AF and those
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receiving anticoagulant or antiplatelet therapy would help to understand the current
practices that are adopted for stroke prevention in NH settings and lack thereof.
Furthermore, identifying factors that are associated with warfarin use may help to target
these factors to develop future interventions to improve anticoagulant therapy in older
adults.

II. Warfarin-Antibiotic Interactions
The purpose of this section is to review the published literature on warfarin-antibiotic
interactions, separately for fluoroquinolones, macrolides and penicillins, in order to
understand and evaluate the current state of knowledge of the clinical significance of
warfarin-antibiotic interactions. MEDLINE, TOXLINE, International Pharmaceutical
Abstracts (IPA), the FDA website and www.guideline.gov, were searched for relevant
literature. The aim of the literature search was to identify studies that have assessed or
reported any interaction between warfarin and quinolones. The search strategy used was
(warfarin AND (quinolones OR ciprofloxacin OR levofloxacin OR moxifloxacin)).
Gatifloxacin was not included because it has been removed from the US market.
Similarly norfloxacin was not included due to its limited use. Articles were included if
they were in English and were original research studies with data from human subjects.
Relevant articles that showed up in the related search and in bibliographies of the
retrieved articles were also included. The search yielded a total of 107 articles from
which 35 were reviews. From the remaining 72 articles, 35 were found to be relevant.

	
  

22	
  

A. Warfarin-Fluoroquinolones Interaction
Most of the evidence for warfarin-fluoroquinolone interactions comes from case reports
or case series and these reports have been summarized in Tables 2, 3, and 4 for warfarinciprofloxacin, levofloxacin and moxifloxacin interactions respectively. As shown in
Table 2, seven case reports or case series, reporting warfarin-ciprofloxacin interactions
have been published.(5-11) These included a total of 9 patients, from which 5 patients
were 70 years or above. There was a marked prolongation of prothrombin time in these
patients, with 2 patients experiencing hematuria or hematemesis.

Four case series or case reports of a warfarin-levofloxacin interaction, involving a total of
11 patients, have been published and have been summarized in Table 3.(12-15) From
these 11 patients, 8 patients were 65 years and above. All 11 patients experienced a
substantial increase in INR values above the therapeutic range. This elevation in INR
resulted in hemopericardium in 2 patients, retroperitoneal bleeding with psoas muscle
bleeding in 1 patient and a case of minor bleeding in another patient. Some strategies that
were used to manage this interaction were warfarin dose reduction, withholding warfarin
therapy and administration of vitamin K and fresh frozen plasma (FFP). There have been
12 reported cases of a warfarin-moxifloxacin interaction as shown in Table 4, and
bleeding events were reported for 2 of these cases.(16, 17)

Since most of the evidence for clinical significance of warfarin-fluoroquinolone
interactions come from case reports they may represent a publication bias and there is
minimal control on confounding factors such as diet, nutritional status, and concomitant

	
  

23	
  

medications in case reports. For example, the pre-antibiotic INR was not reported in
some of the case reports.(11, 15) If the patient’s INR was not stable before the antibiotic
was started, the INR may continue to fluctuate as compared to a patient with stable INR.
The increase in INR may then be incorrectly attributed to the antibiotic for such cases. In
one of the case series, a patient had a fluctuating INR even before moxifloxacin was
started. This fluctuation may have been due to initiation of heparin therapy. Warfarin
therapy had already been discontinued for this patient who was not on concomitant
warfarin-moxifloxacin therapy during INR elevation.(16)

There have been 3 prospective studies to determine the interaction potential between
warfarin and ciprofloxacin.(18-20) The first 2 studies showed that ciprofloxacin did not
alter the pharmacokinetics (PK) or pharmacodynamics (PD) of warfarin and the third
study showed that there was no increase in the patient’s INR. However, since these were
PK/ PD studies they were done in healthy male volunteers and only a single dose of
warfarin and/ or ciprofloxacin was administered to the patients. In addition, healthy
volunteers without any infection are not representative of patients who are normally
prescribed an antibiotic for an active infection. In the presence of certain infections such
as pneumonia, there may be greater inhibition of hepatic enzyme activity,(21) in addition
to suppression of vitamin K producing bacterial flora by the antibiotic in question. These
factors may further interfere with warfarin metabolism and increase the anticoagulant
activity of warfarin. Such effects may not be evident in PK/ PD studies.
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Table 5 is a summary of retrospective and prospective studies that assessed warfarinlevofloxacin interactions. From the 4 retrospective cohort studies that determined the
mean change in INR after administration of levofloxacin to patients on stable warfarin
therapy, 2 studies found a significant increase in mean INR change,(22, 23) whereas the
other 2 did not find a significant change.(24, 25) One prospective study found no
significant increase in INR with the addition of levofloxacin to warfarin therapy in 18
patients with an active infection.(26) However, 9 of the 18 patients had a warfarin dose
adjustment based on the first INR values obtained after start of levofloxacin. For these
patients only the first INR value was used in the analysis, and this may have limited the
ability to identify the effect of levofloxacin on INR values if the interaction occurred after
this INR value had been recorded.

The effect of warfarin-levofloxacin combination on the risk of bleeding has also been
examined in 2 nested case-control studies.(21, 27) The outcome of interest was hospital
admission due to hemorrhage, caused by a warfarin-levofloxacin interaction.(27)
Cefuroxime was chosen as the comparator drug. Patients who were started on
levofloxacin were not more likely to undergo hemorrhage (OR=1.21, 95% CI=0.84,
2.01), unlike those on cefuroxime (OR=1.62, 95% CI= 1.28-2.26). In another similar
nested-case control study assessing the risk of GI bleeding due to warfarin-antibiotic
interactions, levofloxacin was not shown to be associated with an increased risk of
bleeding.(21) Thus both these studies did not show an increase in the risk of clinically
significant hemorrhagic outcomes. Finally, as of January 15, 2004, Health Canada
received 57 reports of suspected coagulation disorders possibly caused by warfarin-

	
  

25	
  

fluoroquinolone interactions.(28) Health Canada is the department of the government of
Canada that is responsible for national public health. From these, 10 cases involved an
interaction with warfarin and ciprofloxacin, 13 involved gatifloxacin, 16 involved
levofloxacin and12 were with moxifloxacin.

Thus based on the literature review of warfarin-fluoroquinolone interactions, most of the
evidence for an interaction comes from case series or case reports and prospective and
retrospective studies suggest that this interaction may not be clinically significant.
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Table 2: Warfarin-ciprofloxacin case reports
Reference

N Mean age
(years)

Mean INR
Change

Mean PT Change
(sec)

Bleeding Complications

Ellis (2000)(5)

2

53

28

15.7

Bilateral subdural hematomas, intractable
epistaxis

Byrd (1999)(6)

1

77

3.17

9.1

Intracerebral bleed leading to death

Kramer (1991)(7)

1

70

-

15.5

None

Renzi (1991)(8)

1

48

-

50.4

None

Jolson (1991)(9)

2

85

-

69

Hematuria

Kamada
(1990)(10)

1

72

-

6.5

None

Mott (1989)(11)

1

72

-

-

Hematemesis
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Table 3: Warfarin- levofloxacin case reports
Reference

N Mean age
(years)

Mean INR
Change

Mean PT Change Bleeding Complications
(sec)

Vadlamudi
(2007)(12)

3

61

5.5

-

Hemopericardium, cardiac tamponade, retropeitoneal
hematoma, death

Jones (2002)(13)

4

62

2.74

-

Epistaxis (1 case)

Ravnan
(2001)(14)
Gheno
(2001)(15)

2

73

3.6

-

None

2

77

-

-

None

Table 4: Warfarin-moxifloxacin case reports
Reference

N Mean age (years)

Mean INR Change

Mean PT Change (sec)

Bleeding Complications

Yildiz (2008)(16)

1

74

10

-

Hematuria and diffuse ecchymosis

Elbe (2005)(17)

5

77

6.7

-

Upper GI bleed (1 case)

Arnold (2005)(29)

3

67

3.5

-

none

O’Connor (2003)(30)

3

80

-

-

none
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Table 5: Summary of warfarin-levofloxacin interaction studies
Reference

N

Mean
Design
age (yrs)

Outcome Measure

Comparator
Drug

Result

Orfila (2009)(31)

21 75

Retrospective
cohort
Retrospective
cohort

Mean change in INR

None

Anticoagulation-related
outcomes a

Gatifloxacin

Nested casecontrol

Hospital admission for
hemorrhage (ICD-9
codes)

Cefuroxime

22 59.5

Retrospective
cohort

Mean change in INR

Felodipine

Glasheen
(2005)(32)

27 69

Retrospective
cohort

Mean change in INR

Terazosin

Yamreudeewong
(2003)(26)

18 68

Prospective
open-label

Mean change in INR

None

Significant increase in INR
(p=0.001)*
No difference in median INR
changes between levofloxacin
and gatifloxacin
No significant increase in
hospital admission for
hemorrhage (OR = 1.21; 95% CI
= 0.84 – 2.01)
No difference in mean change in
INR between levofloxacin and
felodipine (p=0.65)
Significant difference in mean
INR change between
levofloxacin and terazosin
(p<0.01)*
No difference in mean INR
change (p=0.419)

Mathews
(2006)(24)

54 78

Stroud (2005)(27)

-

McCall (2005)(25)

79b

a

Anticoagulation-related outcomes = postfluoroquinolone INR > 4, > goal, ≥ 1 point above goal; INR change 0.5-0.99, 1-1.49, ≥ 1.5
points; vitamin K administration; warfarin dose withheld, warfarin dose reduced, major and minor bleed, ER visits, hospital
admissions, any intervention.
b
Mean age at the start of cohort = 79 years	
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A. Warfarin-Macrolides Interaction
As compared to erythromycin, azithromycin and clarithromycin are considered to be
safer antibiotics to prescribe with warfarin.(33) However, most of the evidence comes
from single case reports and case series and should thus be interpreted with caution, since
they are likely to represent a publication bias. Several case series have reported an
elevation in INR or prothrombin time (PT) when clarithromycin was administered
concomitantly with warfarin.(34-38) Similarly, warfarin-azithromycin interactions have
mainly been reported via case series, as shown in Table 6.(39-43) There have been only
3 retrospective studies that have looked at the potential interaction between azithromycin
and warfarin and these have been summarized in Table 7.(23, 33, 44) Two of these
studies did not find any evidence for a significant interaction between warfarin and
azithromycin.(32, 44) The sample size in these studies was very limited with the largest
study having a sample size of only 52 patients and thus the power to detect a difference in
the INR may have been low for most of them.
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Table 6: Warfarin-azithromycin case reports
Reference

N Mean age (yrs)

Mean INR Change

Mean PT change (sec)

Bleeding Complications

Shrader
(2004)(43)
Williams
(2003)(45)
Foster
(1999)(40)
Woldtvedt
(1998)(39)

1

57

5.5

-

None

1

72

10.4

95.5

Large hematoma

1

71

12.16

-

Right upper quadrant hematoma

1

53

Too high to
quantify

(Maximum PT = 106)

Coughing blood and blood streaked
mucus

Table 7: Summary of warfarin-azithromycin interaction studies
Reference

N

Glasheen
(2005)(23)

Mean age
(years)

Design

Outcome
Measure

Comparator
Drug

Result

32 72

Retrospective
cohort

Mean change
in INR

Terazosin

Significant difference in mean INR
change between groups (p<0.05)*

McCall
(2004)(44)

17 59

Retrospective chart
review

Mean change
in INR

Felodipine

No difference in mean change between
groups (p=0.74)

Beckey
(2000)(33)

26 68.9

Retrospective chart
review

Mean change
in INR

Terazosin

No difference in mean change in INR
between groups (p=0.60)
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C. Warfarin-Penicillins Interaction

There have been very few case reports for warfarin-amoxicillin or warfarinamoxicillin/clavulanic acid interaction.(46, 47) One article reported an interaction
between amoxicillin and acenocoumarol, a coumarin anticoagulant that is not used in the
United States.(48) So far 3 studies have reported either hospitalization due to bleeding or
INR ≥ 6 for amoxicillin/clavulanate for patients on other coumarin anticoagulants, such
as acenocoumarol or phenprocoumon.(49-51) The only study to have assessed the risk of
bleeding with amoxicillin for patients on warfarin was published recently.(52) This study
did not find an association between risk of hemorrhage and use of warfarin-amoxicillin or
warfarin-ampicillin combination. However, Micromedex lists warfarin-amoxicillin/
clavulanate interactions as being of ‘moderate’ severity and the review by Holbrook et al.
list this as a ‘probable’ (class II) interaction.(53)

D. Discussion
The clinical evidence for an interaction between warfarin and fluoroquinolones,
macrolides and penicillins in older adults is very limited and most of the evidence comes
from case reports and case series or from poorly designed retrospective studies. There
were several limitations of the studies that were reviewed in this section. The effect of
increasing age on warfarin-antibiotic interactions was not considered in these studies.
Due to the high prevalence of thromboembolic conditions with increasing age, older
adults represent the highest users of warfarin therapy.(54) In addition, indications such as
urinary tract infections and pneumonia, for which antibiotics are prescribed, are more
prevalent in older adults.(55, 56) Thus adequate representation of older adults in
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warfarin-antibiotic studies may be important. If older age plays an important role in the
potentiation of the drug interactions, it is possible that under-representation of older
adults in some of these studies may have resulted in findings that were not significant.
Since studies conducted so far have included patients with variable age ranges, the
potential for increased anticoagulation due to warfarin-antibiotic interactions in older
patients remains inadequately studied.

The active infection for which the antibiotic is prescribed may also be playing some role
in intensifying the anticoagulant activity of warfarin. The activity of some CYP450
enzymes may be reduced during an infection or inflammation, which may further reduce
warfarin metabolism.(21) Due to the potential role of infection, it may be important to
study warfarin-antibiotic interactions in patients who have an acute infection. However,
across the 4 prospective trials, only 26% of the patients had an acute infection.(57) The
advantage of the retrospective studies was that the subjects had an active infection. The
study by Schellman et al. found evidence for the role of infection in causing an increase
in the bleeding risk for patients on warfarin therapy. This study suggested that infection
or its sequelae, such as fever or reduced vitamin K intake may be responsible for an
increased risk of bleeding since the odds ratio (OR) for the ‘baseline’ risk of bleeding
was already significantly elevated for the subjects before the start date of the
antibiotic.(21) In addition to the indication for which the antibiotic is prescribed, several
other confounding factors are also important to consider while studying warfarin
interactions. Older adults often have multiple comorbidities and use multiple
medications. The decline in renal function with age may also necessitate dose reduction
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of renally eliminated antibiotics such as quinolones. Prospective studies or
pharmacokinetic and pharmacodynamic studies are limited in studying the effect of these
confounders. Thus in addition to studying this interaction in older adults, and in patients
with an infection, there is some value in studying this interaction in clinical settings,
which include patients with multiple disease conditions.

The lack of a control drug or choice of a poor control drug was a common limitation seen
in several studies. Retrospective studies of warfarin-levofloxacin interactions have used
cefuroxime, felodipine and terazosin as the comparator drugs,(23, 25, 27) and studies of
warfarin-azithromycin interaction have used felodipine and terazosin.(33, 44) While
felodipine and terazosin have indications for use that are very different from antibiotics,
the antibiotic cefuroxime was found to significantly increase hospital admissions due to
hemorrhage in patients on stable warfarin therapy. Suitable choice of a control drug is a
challenge, since many antibiotics are implicated to potentially interact with warfarin. Yet
it may be important to assess the interaction effect using a control drug that is an
antibiotic. This is because by comparing a warfarin user who is prescribed an antibiotic to
a warfarin user who is prescribed a different antibiotic, it is possible to study subjects
whose baseline bleeding risks are more comparable. This would help to reduce some bias
due to confounding by indication and also help to distinguish between the effect of a drug
interaction and the effect of infection or its sequelae, such as fever and reduced vitamin K
levels. Although it is a challenge to find a suitable control drug to study warfarininteractions, the importance of using a comparator drug cannot be underestimated.
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Some studies did not use clinically meaningful outcomes such as bleeding events,
hospital admissions, warfarin dose adjustments, or administration of vitamin K. Only
mean change in INR before and after starting the antibiotic was assessed. Although,
increase in INR is an important outcome since a supratherapeutic INR would increase the
risk of a bleeding event, the use of secondary outcomes of over-anticoagulation or
bleeding events may increase our understanding of the clinical significance of these drug
interactions.

E. Conclusion
The most recent review that evaluated the possibility of increased anticoagulation due to
warfarin-fluoroquinolone interactions concluded, “There are no consistent data to support
the claim of an increased anticoagulation response in patients receiving warfarin and any
of the three commonly prescribed fluoroquinolones”.(57) However, most of the studies
included in this review had varied age ranges and may not adequately represent the older
adult population. The prospective trials of concomitant administration of levofloxacin
and ciprofloxacin in patients on warfarin did not demonstrate an increased
anticoagulation response.(19, 20, 26) Meanwhile, the retrospective studies showed either
significant increased elevation in INR,(23-25, 31) or significantly increased risk of
hemorrhage.(27) However, these studies were not specifically done in older adults. Only
3 studies of warfarin-levofloxacin were done in older adults from which 2 showed
evidence of an interaction,(24, 27) and 1 failed to show significant bleeding outcomes
due to this interaction.(21) An outcome of a bleeding event always has to be considered
in light of the patient care environment. If the dose is lowered due to an elevated INR,
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then a bleeding event was avoided. Thus even though a warfarin-quinolone interaction
may not result in adverse bleeding outcomes for all patients, over-anticoagulation caused
by elevations in INR may still be an important outcome to consider for older patients due
to the risks of hemorrhagic events associated with elevated INR.(58)

F. Significance
Changes in tissue distribution, declining renal function and presence of chronic disease
states that require long-term drug therapy may put older adults at a higher risk for drugdrug interactions that may result in significant ADEs. Although warfarin clearance is not
affected by a decline in renal function, serum levels of potentially interacting drugs, such
as ciprofloxacin and levofloxacin may increase, thus enhancing the likelihood of a
clinically significant interaction. Yet studies on warfarin-antibiotic interactions have not
examined the effect of increasing age on the risk of over-anticoagulation or bleeding
outcomes. Awareness of the differences in PK and PD profiles of warfarin and
quinolones and the potential risk of this interaction in older adults may guide clinicians in
making appropriate treatment choices while co-prescribing antibiotics with warfarin.
Older adults are taking multiple medications for multiple co-morbid conditions. They are
physically frailer, have poor nutritional status and due to their high risk of falls, the risk
of bleeding events may be higher.

The levels of warfarin monitoring required for vulnerable older adults may be higher due
to increased sensitivity to warfarin effects. Potential warfarin antibiotic interactions may
further complicate the clinical management of warfarin therapy in older adults.
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Physicians managing an older patient’s warfarin therapy may sometimes be unaware of
the co-prescription of antibiotics with warfarin due to the short course of therapy with
antibiotics. Furthermore, it is possible that the risk of a warfarin-antibiotic interaction
may be higher in older adults with multiple co-morbid conditions or for those taking
multiple medications. In spite of the risks associated with warfarin use and the frequency
with which it is prescribed in older adults, there are few precise estimates of the outcomes
associated with co-prescribing potentially interacting medications such as antibiotics with
warfarin. Thus the evidence base underlying the risk of warfarin-antibiotic interactions in
older adults is weak and there is room for further research to better understand this risk.

The next section is a literature review to determine the effect of increasing age on
warfarin-antibiotic interactions in older adults. The literature has been reviewed to
describe general pharmacokinetic and pharmacodynamic changes that occur in older
adults and the effect of increasing age on the pharmacodynamics of warfarin and on the
pharmacokinetics of fluoroquinolones. Fluoroquinolones were chosen as the class of
antibiotics to review in detail because age-related changes in pharmacokinetics of
fluoroquinolones have been documented more often than the other antibiotics. This
section also provides an understanding of how these factors may play a combined role in
potentiating the risk of warfarin-antibiotic interactions in older adults. Two cases have
been presented as examples in order to provide a real clinical scenario.
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III. Potential Effect of Age on Warfarin-Fluoroquinolones
Interactions
Several medications may undergo a pharmacokinetic (PK) or pharmacodynamic (PD)
interaction with warfarin, thus increasing the risk of a bleeding event. Fluoroquinolones
are a widely used class of antibiotics in older adults and reports of an interaction between
warfarin and fluoroquinolones have been conflicting and inconsistent. The risk of an
interaction may be higher in older adults due to age-related physiologic changes that may
result in altered PD response for warfarin and altered PK of fluoroquinolone antibiotics.
A search for relevant articles using PubMed (1975-2011) and International
Pharmaceutical abstracts (1975-2011) was conducted in order to review articles on agerelated PK and PD changes in fluoroquinolones and warfarin and the possible
mechanisms of the interaction. Case reports and evidence from other coumarin
anticoagulants were excluded. The literature suggests an age-related increase in
sensitivity to warfarin response and an age-related reduction in clearance of
fluoroquinolones, due to declining renal function in older adults. The mechanism of
warfarin-fluoroquinolone interactions has not been fully elucidated but higher drug
exposure of warfarin and fluoroquinolones due to PK-PD changes may potentiate this
interaction in older adults. Reports of warfarin-fluoroquinolone drug interaction studies
in older adults are limited thus highlighting the need for studies that examine the effect of
increasing age on the risk of over-anticoagulation or bleeding outcomes due to warfarinfluoroquinolone interactions. This would lead to a better understanding of the
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contribution of age-related PK-PD changes to this interaction. Finally, this may aid
clinicians in making suitable treatment decisions while co-prescribing antibiotics with
warfarin and may assist healthcare providers in anticoagulation clinics to better manage
this potential drug interaction in older patients.

A. Case Presentations
A 72-year-old white male with atrial fibrillation was diagnosed with bronchitis. He was
on stable warfarin therapy with a target INR range from 2.0 – 3.0. His weekly warfarin
dose was 82.5mg and he was prescribed moxifloxacin 400 mg daily for 10 days to treat
his bronchitis. In the one month prior to initiation of moxifloxacin his INR ranged
between 2.0 and 2.4. However, following commencement of moxifloxacin his INR
peaked to 6.5. His warfarin dose was withheld for 3 days and a large bruise was observed
on patient’s arm. A review of other concomitant medications revealed that moxifloxacin
was the only potentially interacting medication that the patient was prescribed, suggesting
that it may have caused the elevation in INR in this older patient.

An 83-year-old white male with a history of deep vein thrombosis and pulmonary
embolism was on stable warfarin therapy with a target INR range from 2.0 – 3.0. His
weekly warfarin dose was 10 mg. He was prescribed levofloxacin 500mg daily for 7 days
for pneumonia. Prior to initiation of the antibiotic his INR of 2.6 was within his target
range. However, on day 5 of levofloxacin therapy his INR rose to 8.0. Following this
elevation his warfarin dose was withheld for 3 days and his INR was rechecked before
initiating warfarin therapy. An elevation in INR in this older patient may be caused as a
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result of a drug interaction between warfarin and levofloxacin, since the patient was not
prescribed any other potentially interacting medications with warfarin.

B. Introduction
Warfarin is the most widely used oral anticoagulant and its use is higher in older adults
due to increased prevalence of atrial fibrillation and other thrombotic disorders with
advancing age.(54) In an analysis of national estimates of emergency department (ED)
visits for adverse drug events in patients aged 65 years or older, 17% of all visits were
from adverse drug events (ADEs) caused by warfarin, such that warfarin accounted for
the highest rates of ED visits in this older adult population.(59) Ciprofloxacin,
levofloxacin and moxifloxacin are the most widely used fluoroquinolone antibiotics in
older adults.(60) Due to their potential to increase the anticoagulant activity of warfarin,
co-prescription of quinolones with warfarin may cause a drug-drug interaction.(61)
However, the clinical significance of warfarin-quinolone drug interactions has been
questioned and the reports have been conflicting.(57) Yet warfarin-quinolones
interactions were ranked as the fourth most dangerous drug interactions in a list of the top
10 dangerous drug interactions in nursing home residents. This list was developed as an
initiative of the Multidisciplinary Medication Management Project.(62)

Since warfarin and antibiotics such as quinolones are commonly implicated for resulting
in ADEs and due to the high rate of concurrent use of these medications in older
adults,(63) it is important to understand if there exists a potential for a clinically
significant drug-drug interaction in older adults. Increasing age is associated with several
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pharmacokinetic (PK) and pharmacodynamic (PD) changes that may affect drug
exposure in the older patient. A majority of the drug-drug interactions that affect older
adults involve both PK and PD mechanisms. Thus the associated PK and PD changes in
older adults may increase the potential of occurrence of an adverse event resulting from a
drug-drug interaction. In addition, the adverse consequences of the drug-drug interaction
may be more severe in older adults, especially frail older patients, since their physiologic
reserve is already diminished. This review describes general pharmacokinetic and
pharmacodynamic changes that occur in older adults, the effect of increasing age on the
pharmacodynamics of warfarin, pharmacokinetic changes for fluoroquinolones with
increasing age and how these factors may play a combined role in the mechanism of
warfarin-quinolone interactions and potentially increase the risk of this interaction in
older adults.

C. Method
The databases searched included PubMed and International Pharmaceutical Abstracts
from the period, January 1975 to June 2011, using key words aged, frail elderly,
pharmacokinetics, pharmacodynamics, warfarin, fluoroquinolones, quinolones, drug
interactions and hemorrhage. Only English-language articles were included. Clinical
trials and prospective and retrospective observational studies were included. Case reports
and case series were excluded. Studies with a focus on other oral anticoagulants, such as
phenprocoumon and acenocoumarol, were excluded from the review. Bibliographies of
included articles were manually searched for additional studies that may be relevant.
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D. General Pharmacokinetic and Pharmacodynamic Changes with Aging
For most drugs absorption is not significantly altered with aging.(64) Aging is associated
with a decrease in the total body water as a proportion of body weight, which results in a
reduction of the volume of distribution of water-soluble medications; thus increasing
their serum concentrations in the older patient. With an increase in total body fat with
aging, lipid soluble drugs have a larger volume of distribution and tend to remain in the
body for longer periods. However, protein binding of drugs is not significantly affected
by aging.(65) Liver oxidative metabolism of drugs is often reduced in older patients,
mainly due to reduced blood flow to the liver (~20-50%) and reduced liver size (~2030%).(64) The CYP450 enzyme system is responsible for the metabolism of warfarin and
some fluoroquinolones, and intrinsic activity (oxidative metabolism) for this enzyme
system is believed to be lower in older adults, compared to young adults.(66)
Furthermore, renal function declines with age, thus necessitating dose reduction of
certain renally eliminated medications in older patients. The Cockcroft-Gault equation is
used to dose medications in older patients based on their creatinine clearance. However,
this equation may overestimate renal function for frail patients, since their muscle mass is
markedly decreased.(64)

There is a lack of general understanding of pharmacodynamic changes in aging since
these changes have not been well studied. The older patients’ response to drug therapy is
generally affected by aging and disease-associated physiological changes. PD changes
may occur due to changes in receptor affinity for medication, or post-receptor events such
as altered signaling. In the case of warfarin, PD changes in older adults are mainly due to
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altered homeostatic control mechanisms.(67) In some situations, PD changes may cause
adverse drug events (ADEs) in older patients.

E. Effect of Age on Pharmacodynamic Response to Warfarin
Direct pharmacodynamic studies to determine the response to warfarin therapy are
challenging as a result of a delayed therapeutic effect, which is mainly due to its
mechanism of action. In addition, the effect of warfarin is sensitive to diet-associated
changes in levels of vitamin K.(67) There is sufficient evidence from epidemiologic
studies to suggest the association between older age and increased anticoagulant
response, as a result of an increased sensitivity to warfarin with increasing age. Such an
age-associated increase in sensitivity to warfarin has been demonstrated in an early
pharmacodynamic study.(68) This was a prospective study of 4 older adults (age range
62-89 years) and 4 young (age range 27-37 years) patients who were administered a
single loading dose of warfarin. The anticoagulant response, as measured by vitamin Kdependent prothrombin complex activity (PCA) using the Thrombotest procedure, was
found to be greater in older patients as compared to younger patients. This was in spite of
administering lower, weight-adjusted doses to the elderly. In addition, synthesis of
vitamin-K dependent clotting factors was inhibited to a greater extent in older patients, at
the same warfarin plasma concentrations as the younger patients. No age-related
differences in warfarin pharmacokinetics were evident in this study. Thus, in addition to
demonstrating the increased sensitivity to warfarin with age, this study demonstrated the
mechanism of this altered sensitivity in older patients. The potential effect that coexisting
clinical or medication factors may have on warfarin sensitivity could not be determined
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in this study. In addition with increasing age these factors may further exaggerate
warfarin response in older patients.

An age-related increase in sensitivity to warfarin has also been demonstrated in a
prospective cohort study of 530 patients from a university outpatient anticoagulation
clinic, over a 10-year period.(69) Results from the multivariate linear regression model
suggested that anticoagulant response to warfarin therapy, as determined by the doseadjusted mean PT ratio, was found to be exaggerated for older patients in the 60-69 and ≥
70 years age group as compared to those < 50 years (p<0.001). Furthermore, the mean
daily warfarin dose declined substantially with increasing age (6.4 mg/day for patients <
50 years vs. 3.6 mg/day for patients ≥ 70 years; p<0.001). However, this study did not
demonstrate the mechanism for increase warfarin sensitivity in older adults.

Several other studies have also demonstrated similar age-related changes in warfarin dose
requirements.(70-73) Husted et al. concluded that the difference between the mean daily
warfarin maintenance dose between patients aged 50-60 years and 61-70 years was
significantly different (p<0.05) in their study of 114 patients on long-term anticoagulant
therapy.(70) In a longitudinal study of 104 patients on stable warfarin therapy, a
significant fall in warfarin requirements over time was observed, such that differences in
warfarin dose requirements were significantly correlated with age differences (r=0.25,
p<0.01).(71) The superiority of such a longitudinal study is its ability to identify true agerelated changes in dose requirements using the same subjects over time. However, the
low ‘r value’ indicates that age alone does not explain the fall in dosage requirement.
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Similarly, the studies by Garcia et al. and Kamali et al. have also shown a significant
correlation between decreasing dose and increasing age (p<0.001 and r = -0.42, p
<0.0001 respectively).(72, 73)

The evidence for significant age-related changes in warfarin dose requirements may
partly be explained by the increased sensitivity in warfarin response observed with
increasing age. The exact mechanism of the age-related changes in warfarin activity is
not known. However, two of the studies have attributed it to lower levels of vitamin K
dependent coagulation factors in older adults.(68, 70) Furthermore, the higher prevalence
of acute and chronic illnesses such as hypertension, peptic disease, liver disease,
malignancy, cerebrovascular disease and serious heart disease in older adults may further
increase the anticoagulant intensity of warfarin and thus increase the risk for serious
bleeding.(74) For example, an age-related hepatic dysfunction may potentially increase
the response to warfarin through impaired synthesis of clotting factors and through
decreased metabolism of warfarin.(75) Thus age may have a potentially confounding
effect on the risk of bleeding in older adults with several co-morbid conditions.

F. Safety of Warfarin Therapy in Older Adults
The trend towards increased bleeding in older patients, especially intracranial
hemorrhage, has been suggested in several studies.(76-79) The safety of treatment with
warfarin in older patients has been well documented in a systematic review.(80) Out of
the 8 studies that compared the incidence rate of bleeding in older adults to younger
individuals in this review, 7 found the incidence rate of bleeding to be almost 2 fold
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higher in older adults as compared to younger patients, suggesting that there is a need to
exercise caution with the use of warfarin in older patients. Similarly, increasing age has
been implicated as a risk factor for increased bleeding experienced by older patients.(74)
In addition, the authors reported that concomitant use of several medications in older
adults was also believed to further increase the risk of bleeding.

G. Effect of Age on the Pharmacokinetics of Fluoroquinolones
Age-related physiologic changes have the potential to affect the pharmacokinetics of
fluoroquinolones. The most important physiologic change in older adults that affects the
pharmacokinetics of fluoroquinolones is the decline in renal function. Reduced renal
function, as a result of reduced glomerular filtration rate, is associated with the aging
process.(81) Co-morbid medical conditions may exacerbate this decline further.
Glomerular filtration rate is estimated by the patient’s creatinine clearance and the
reduction in creatinine clearance in almost 40% when old (>80 years) patients are
compared to middle-aged patients.(60) This leads to a reduced clearance of drugs such as
fluoroquinolones that are renally excreted. Levofloxacin is an example of a
fluoroquinolone that is predominantly renally excreted and compared to other
fluoroquinolones levofloxacin is the most dependent on renal excretion for elimination.
High plasma concentrations of levofloxacin are normally achieved for elderly patients at
recommended doses for younger individuals.(82) Early PK studies of levofloxacin have
mainly attributed significant differences in PK parameters between younger individuals
and older adults, to differences in renal functions among the subjects.(82) However,
results from PK studies done in healthy older adults may not be entirely applicable to
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older adults with several co-morbid conditions or to frail older adults. In a study of 183
hospitalized patients with community-acquired pneumonia (CAP), elderly patients
receiving levofloxacin demonstrated significantly lower clearance (7.2 ± 1.8 vs. 10.4 ±
3.6, p <0.05), greater elimination half-life (9.8 ± 2.5 vs. 7.4 ± 2.5, p<0.05) and higher
area under plasma concentration-time curve (AUC)/ minimum inhibitory concentration
ratios (49.9 ± 9.7 vs. 34.8 ± 9.4, p<0.05) compared to younger patients.(83)

Ciprofloxacin on the other hand, is excreted unchanged renally (60-70% of total serum
clearance) as well as extra-renally by hepatic routes.(60) In a study that included elderly
patients and patients with renal impairment, the half-life of ciprofloxacin was almost two
times the half-life in younger patients (3-4 hours).(84) Ciprofloxacin undergoes
metabolism via the CYP1A2 and CYP3A4 enzymes. The less potent isomer of warfarin
(R-warfarin) is also metabolized by CYP1A2 and CYP3A4.(58) It is generally believed,
that aging decreases hepatic metabolism of medications through CYP1A2 and CYP2C19
pathways, and hepatic metabolism either decreases or remains normal for medications
undergoing metabolism via CYP3A4 and CYP2C9. Substantial changes in ciprofloxacin
metabolism have not been clearly demonstrated in older adults. However, if ciprofloxacin
and warfarin are inhibiting and competing for the same metabolic pathway, there exist a
potential for a clinically significant drug interaction. In addition, following a single oral
250mg dose, the absolute bioavailability of ciprofloxacin was found to be significantly
higher in older adults compared to younger patients (72% vs. 58%).(60)
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Finally, age does not have a significant effect on the PK of moxifloxacin since
moxifloxacin is predominantly metabolized by phase II (conjugation) reactions and
increasing age does not appear to have an effect on phase II metabolism of drugs.(65)
Only 15-22% of moxifloxacin is excreted in the urine and no significant decrease in its
clearance was observed in older subjects with renal function decline.(85) In conclusion, a
decline in renal function with increasing age leads to reduced clearance of certain
fluoroquinolones and dosage adjustments may be recommended for such patients. In
addition, patients above >80 years and those with reduced lean body mass, such as frail
older patients, should almost always have their quinolone doses adjusted. This is mainly
due to age-related changes in PK for quinolones that may potentially lead to higher drug
exposure.

H. Potential Mechanism of Warfarin-Fluoroquinolone Interactions
Several mechanisms have been proposed for a drug interaction between warfarin and
antibiotics. Putting these proposed mechanisms into perspective for an older adult would
help to understand how the risk for a drug interaction might be modified with increasing
age. CYP1A2 and CYP3A4 enzymes metabolize the less potent isomer of warfarin, i.e.
R-warfarin.(86) Firstly, fluoroquinolones are inhibitors of CYP1A2 activity and may thus
inhibit metabolism of warfarin in this manner.(53) Since aging may decrease hepatic
metabolism of medications through CYP2C9,(65) this may further inhibit metabolism of
warfarin in older adults. Either or both of these mechanisms may result in increased drug
exposures for warfarin in older adults. Secondly, antibiotics may impair the production of
vitamin K by the gastrointestinal flora,(86) Vitamin K is required for coagulopathy and
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their levels in the body are primarily determined by dietary intake.(86) During an
infection or in a frail older patient with poor nutritional status, dietary vitamin K levels
are generally low and may thus lead to increased warfarin sensitivity and overanticoagulation. Vulnerable older adults may require closer monitoring with concomitant
antibiotic use, especially if they are prone to more serious sequelae such as falls resulting
in serious bleeding events.

Finally, the effect of the infection on warfarin metabolism cannot be underestimated.
During an infection or inflammation the activity of some CYP450 enzymes may be
reduced. This may occur due to the secretion of cytokines such as tumor necrosis factor
(TNF) and interleukins (ILs) which could down-regulate CYP450 enzyme activity, thus
reducing the metabolism of warfarin.(21) Thus the underlying infection for which the
antibiotic is prescribed may affect the clearance of warfarin. This is especially true in the
case of pulmonary infections such as pneumonia, since hepatic metabolism of drugs is
reduced in the presence of pneumonia.(21) The incidence of community-acquired
pneumonia has been shown to increase significantly with age, such that almost 80% of all
cases are in those above 60 years.(55) Similarly, the frequency of urinary tract infections
is the highest in older adults.(56) Furthermore, due to appetite suppression during an
infection, vitamin K levels may also be low. Thus increased exposure to warfarin and
quinolones associated with increasing age, increased sensitivity to warfarin in older
adults, and effect of age on vitamin K and coagulation may result in an increased risk of
warfarin-quinolone interactions in older adults.
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I. Discussion

	
  

There is an age-related increase in sensitivity to warfarin response and the mechanism for
this has not been entirely established. A possible reason is that older adults may have
lower levels of vitamin K dependent coagulation factors. Reduced renal function
associated with increasing age may reduce the clearance of the quinolone antibiotics.
These factors combined may potentially lead to higher drug exposure for both warfarin
and quinolones in older adults. Thus an interaction between warfarin and quinolone
antibiotics in older adults may potentially result in significant elevations of INR and put
them at greater risk for hemorrhagic complications. Given that hemorrhagic
complications of warfarin are higher in older adults, understanding the clinical
significance of the interaction between these two widely used medications may
potentially help to improve the management of warfarin-antibiotic interactions in older
adults. Thus there is a need for research in the area of warfarin-quinolones druginteractions in older adults, rather than extrapolating what we already know from younger
populations regarding the clinical significance of this drug interaction. The research
proposed in this application is significant because it will help us to understand the clinical
relevance and the risk of co-prescribing warfarin and antibiotics specifically in older
adult, since they may be the population with a greater risk.
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CHAPTER 3
Warfarin Use in Nursing Home Residents: Results from the
2004 National Nursing Home Survey
I. Abstract
Background: Practice guidelines recommend anticoagulation therapy with warfarin for
stroke prevention in patients with atrial fibrillation (AF). Despite this, warfarin is
underused in older adults.
Objective: To determine the prevalence of AF in nursing home (NH) residents and use of
warfarin or other anti-platelet medications in NH residents with AF, with indications for
and without contraindications to warfarin use. The secondary objective is to determine
the factors associated with warfarin use in NH residents with AF.
Methods: Cross-sectional analysis of prescription and resident data files from the 2004
National Nursing Home Survey was performed. Residents with a diagnosis of AF were
identified using ICD-9-CM codes and prescriptions of warfarin and anti-platelet
medications were identified using Long-term Care Drug Database System (LTCDDS)
codes. Resident characteristics, stroke risk factors and potential bleeding risk factors
significant at p<0.10 in chi-square analyses were entered in the final multiple logistic
regression model to determine the factors associated with warfarin use. All analyses were
done using SAS 9.2.
Results: From 13,507 NH residents, 1904 (14%) had a diagnosis for AF and 1767 (13%)
had a diagnosis for AF, with indications for and without contraindications to warfarin
use. Of these 1767 residents, 30% were prescribed warfarin and of the remaining 1230
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resident, 23% received either aspirin or clopidogrel, such that 54% of residents with AF
did not receive any antithrombotic therapy in the form of warfarin, aspirin, clopidogrel or
combination of these medications. Factors that were significantly associated with
increased odds of receiving warfarin were congestive heart failure, previous stroke/
transient ischemic attack, deep vein thrombosis/ peripheral embolus, valvular heart
disease and total number of medications (≥ 6). Factors that were significantly associated
with reduced odds of receiving warfarin were non-white race, history of gastrointestinal
bleeding and use of anti-platelets (i.e. clopidogrel).
Conclusions: AF is common in NH residents and more than half the residents with AF,
with indications for and no contraindications to warfarin use, were not prescribed either
warfarin or anti-platelets such as aspirin or clopidogrel, suggesting that anticoagulation
therapy may be underused in NH residents with AF.
Keywords: Warfarin, atrial fibrillation, underuse, nursing homes
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II.

Introduction

The Anticoagulation and Risk Factors in Atrial Fibrillation Study (ATRIA) study,
estimated that approximately 2.3 million Americans were diagnosed with atrial
fibrillation (AF) between 1996-1997, and this number is likely to increase 2.5 fold in the
next 50 years.(1) The age-specific prevalence of AF is the highest in those above 80 years
(11-12%) as compared to those 55 years and younger (0.1-0.2%).(2) Patients with AF
have a five-fold increased risk of ischemic stroke; thus prevention of ischemic stroke is
the primary goal in management of patients with AF. (2) Practice guidelines recommend
anticoagulation therapy with a vitamin K antagonist, such as warfarin, for the prevention
of ischemic stroke in these patients.(3-5) For patients who are at increased risk of
bleeding events or have a contraindication to warfarin, anti-platelet therapy with aspirin
may be an alternative, although aspirin is not as effective as warfarin in reducing the risk
of stroke in AF patients.(6, 7) The combination of aspirin and clopidogrel was found to
be more effective than aspirin alone and may be used in patients for whom warfarin is
contraindicated.(8) In addition, long-term use of clopidogrel was considered more
effective than aspirin alone in reducing the risk of thromboembolic events.(9) Ticlopidine
is no longer used for anti-platelet therapy and according to the Beers criteria its use is
discouraged in older adults.(10) Therefore, adjusted-dose warfarin still remains the most
effective therapy for stroke prevention.

Currently, more than 1.6 million older Americans are residing in nursing homes. The
prevalence of AF is also higher in NH residents (7.5-17%) as compared to community-
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dwelling older adults.(14, 16) This may be a reflection of the higher age and increased
prevalence of cardiovascular diseases among NH residents. In addition, NH residents are
generally frailer as compared to community-dwelling older adults. Frail patients are less
likely to receive warfarin, and this may partly be due to fear of hemorrhagic
complications.(17) The relationship between increasing age and hemorrhagic
complications is such that the tendency towards increased bleeding with oral
anticoagulants is higher in older adults as compared to younger patients.(18) In addition
to the increased incidence of bleeding, the severity of bleeding events has been shown to
be greater in older adults.(19) Several studies have shown that the response to warfarin
therapy increases with age, both in the early induction phase and during the long-term
maintenance phase.(20) Age-related changes in warfarin dose requirements have been
demonstrated in cross-sectional studies, (21-25) as well as in longitudinal studies.(22, 26)
The risk of falls is higher in NH residents, such that the mean fall rate of 1.5 falls/ bed per
year is three times the rate for community-dwelling older adults.(27) Higher prevalence
of co-morbid conditions such as, congestive heart failure, hypertension, malignancy,
ischemic stroke, peptic ulcer disease, liver disease, in older adults may also lead to an
increased risk of bleeding.(19, 20) Thus, changes in homeostasis of coagulation
associated with increasing age, increased fall risk and high prevalence of multiple comorbid conditions may put NH residents at an increased risk of bleeding events. Due to
perceived increased risk of bleeding, nursing home residents may be less likely to receive
a prescription for warfarin, in spite of the presence of more than one stroke risk factor.
Gurwitz et al have shown adverse warfarin-related events to be common among NH
residents, of which 29% were judged to be preventable.(28) However, the benefits of
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warfarin therapy in reducing the incidence of thromboembolic stroke have been
demonstrated for patients with AF who do not have contraindications to warfarin,
including patients that are 70 years and older.(29-31)

Despite the benefits of anticoagulation therapy with warfarin in AF patients, studies have
reported an under-use of this drug in older adults.(11-13) Few studies have specifically
documented the prevalence of AF and under-use of warfarin in NH residents and none of
these used a nationally representative sample of NH residents.(14-16, 32) Some of these
studies were done more than 10 years ago, and since then new anti-platelet agents such as
clopidogrel have become available for secondary stroke prevention. Thus there is limited
national level data on the prevalence of AF and use of warfarin in NH residents. The NH
population is of interest due to their higher mean age and thus higher prevalence of AF.
In addition, the increased prevalence of cardiovascular diseases in this population is a
concern since some of these conditions may be potential stroke risk factors. Determining
patterns of warfarin and anti-platelet medication use in NH residents would increase our
understanding of treatment choices made for stroke prevention in this older population.
Identifying resident characteristics or risk factors for stroke and bleeding that are related
to warfarin use may further help to address the issue of underuse of anticoagulation
therapy, if any. Therefore, the primary aim of this study was to determine the prevalence
of AF in nursing home residents and use of warfarin or other anti-platelet medications in
NH residents with AF, with indications for and without contraindications warfarin use.
The secondary aim is to determine the factors associated with warfarin use in NH
residents with AF.
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III.

Methods

A. Data source and study sample: This is a cross-sectional analysis of the prescription
and the resident data file from the 2004 National Nursing Home Survey (NNHS). This
survey uses two-stage sampling to obtain a representative sample of nursing home
residents in the United States and is conducted periodically by the Centers for Disease
Control and Prevention. The 2004 data is the more recent wave of the NNHS and
contains information on 13,504 nursing home residents. The NNHS dataset is available
for public use and was accessed after receiving approval from the Virginia
Commonwealth University Institutional Review Board. More details of the NNHS may
be found at http://www.cdc.gov/nchs/nnhs.htm.

The study sample included a nationally representative sample of NH residents with AF.
Residents with a diagnosis for AF were identified using the International Classification
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 427.31. AF coding
has been shown to have high sensitivity (81-91%) and specificity (83-100%) in a
previous study that determined the accuracy of coding of stroke risk factors such as AF,
by using ECG and physician history notes as the gold standard.(33) This study was not
specific to the NNHS, but previous studies have also used the ICD-9-CM diagnostic code
427.31 to identify eligible patients with AF from large claims databases,(13, 34) or from
hospital notes and discharge records.(12, 35)
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From the full AF sample, residents for whom warfarin was not indicated according to the
2001 American College of Cardiology/ American Heart Association (ACC/AHA)
guidelines for management of patients with AF were excluded.(36) The 2001 guidelines
were applicable at the time of the 2004 NNHS sample. According to the ACC/ AHA
guidelines, warfarin was not recommended for men and women < 60 years of age with or
without stroke/ thromboembolism risk factors and men 60-74 years of age without
thromboembolism/ stroke risk factors. This sample was further reduced to those residents
for whom warfarin is indicated, i.e. women 60-74 years of age with or without stroke/
thromboembolism risk factors, men 60-74 with stroke/ thromboembolism risk factors and
both men and women 75+ with and without stroke/ thromboembolism risk factors.
Stroke/ thromboembolism risk factors included congestive heart failure, hypertension,
diabetes mellitus, previous stroke or transient ischemic attack (TIA), coronary heart
disease, deep vein thrombosis or peripheral embolus and valvular heart disease. The
stroke risk for each resident with AF was also calculated using the CHADS2 (congestive
heart failure, hypertension, age ≥ 75 years, diabetes mellitus and prior stroke or transient
ischemic attack) index. This score is usually calculated to quantify the stroke risk for
patients with AF and may help to guide suitable antithrombotic therapy.(37)

In addition, residents for whom warfarin is contraindicated according to the Coumadin®
package insert were excluded.(38) These contraindications included hemorrhagic
tendencies or blood dyscrasias such as thrombocytopenia, active GI ulceration and recent
surgery. Furthermore, variables for potential bleeding risk factors were created. These
included age ≥ 65, renal failure/ chronic kidney disease, falls history, dementia, hepatic
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disease, history of gastrointestinal bleeding, myocardial infarction, malignancy, use of
warfarin interacting medications such as anti-platelets (i.e. clopidogrel) and NSAIDs.
These potential bleeding risk factors were identified from the Coumadin® package insert,
the Outpatient Bleeding Risk Index and the HAS-BLED score.(38-40) Variables for
thromboembolism risk factors, contraindications for warfarin use and potential bleeding
risk factors were created using information from primary and secondary diagnoses for
NH admission and recent ER visits/ hospitalization from NNHS resident questionnaire
and LTC medication data. The ICD-9-CM diagnosis codes used to identify residents with
the above variables have been provided in Appendix A. These codes have been validated
in previous studies and were identified using the ICD-9 coding manual and previous
literature.(33, 41-48) These ICD-9 codes have been used previously in other studies.(49,
50) In addition to ICD-9 codes, NAMCS reason for visit codes were used to identify
residents with contraindications to warfarin use. (Appendix B) A resident was said to
have a positive fall history if they had a documented fall in the past 31-180 days, as per
the definition used by the 2004 NNHS. Use of anti-platelets and NSAIDs were
determined using the LTCDDS codes listed in Appendix C.

B. Drug exposure: The NNHS collected medication data using the medication
administration records (MARs) in the resident’s medical record. For each sampled
resident the designated NH respondent answered medication questions such as ‘what
medications were taken by the resident during the 24 hours the day before the facility
interview?’ and ‘what medications were taken regularly by the resident but not during the
24 hours before the facility interview?’ The interviewer was allowed to enter up to 25
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medications for each question using the computer-assisted personal interviewing (CAPI)
instrument. The primary outcome of this analysis is the use of warfarin in NH residents
with AF, with indications for and without contraindications to warfarin use. The Longterm Care Drug Database System (LTCDDS) codes were used to determine whether
residents with AF received a prescription for warfarin or other anti-platelet agents, such
as aspirin (at daily dose from 81mg to 325 mg to distinguish from its use as an analgesic
and anti-inflammatory), clopidogrel, ticlopidine and dipyridamole. The LTCDDS codes
for the above medications are provided in Appendix C and were used to scan all 25
medications for each sampled resident. Prevalence of warfarin use and use of other antiplatelet drugs in these residents with AF was determined.

C. Statistical analysis: The prescription and resident data files were merged for the
purpose of the analysis based on the resident ID (RESNUM). Sampling weights were
provided in the NNHS, and these were used to determine national estimates of
medication use and prevalence. Descriptive statistics were used to summarize the
characteristics of residents with AF. Since the data were normally distributed, mean and
SD were used to describe continuous outcomes. Thus the dependent variable in this
analysis was prescription of warfarin. Chi-square analysis was used to determine the
association between warfarin use and resident characteristics such as age (60-79, 80-90,
≥90), sex, race (white and non-white), ethnicity (Hispanic and non-Hispanic), length of
stay (≥ 90 days, < 90 days), total number of medications (0-5, 6-15, 16-30), stroke risk
factors (congestive heart failure (CHF), hypertension, diabetes mellitus, previous stroke
or TIA, DVT or peripheral embolus, valvular heart disease, CHADS2 score (0-1, 2, 3, 4-
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5) and potential bleeding risk factors (renal failure/ CKD, dementia, history of falls,
bleeding history, myocardial infarction, malignancy, use of anti-platelets or NSAIDs).
Total number of medications was classified as either 0-5, 6-15 or 16-30, since surveys on
patients living in nursing homes showed that these residents took on average 6-8 different
drugs simultaneously. (51) Thus we would expect a majority of NH residents to be within
the 6-15 category of total number of medication. The significance level for variables in
the bivariate chi-square analysis was set to alpha = 0.10. Factors that were found to be
significantly associated with warfarin use in the bivariate chi-square analysis were
included in the final multiple logistic regression model. Model building was done using
the stepwise selection option under PROC LOGISTIC with SLENTRY (significance
level for entering) set at 0.10 and SLSTAY (significance level for stay) set at 0.15. All
analyses were conducted using SAS software, version 9.2 (SAS Institute Inc, Cary, NC,
USA). P-values < 0.05 were considered significant. Survey procedures such as
SURVEYMEANS, SURVEYFREQ and SURVEYLOGISTIC were used, since these
procedures take into account the sampling weights.

IV.

Results

A. Demographics and Anticoagulant Use
From the 13,507 NH residents sampled in the 2004 NNHS, a total of 1904 (14%)
residents had a diagnosis for AF. Of these 1904 residents with AF, 64 (3.4%) residents
did not have any risk factors for stroke and were excluded from the analytic sample.
Further from the remaining 1840 residents with an indication for warfarin use, 1767
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residents had no contraindications to warfarin use. Thus from the total 13,507 NH
residents, 1767 (13%) had a diagnosis for AF with indications for and no
contraindications to warfarin use. The mean age (SD) of 1767 residents with AF was 85.6
(7.4) years and the range was 61-100 years. From this, 1259 (71%) residents were
females. The mean (SD) number of medications prescribed for residents with AF was 10
(4) and the range was 0-24 medications.

Warfarin was prescribed in 537 (30%) residents with AF and of the remaining 1230
(70%) who did not receive warfarin, 278 (23%) received anti-platelet therapy either in the
form of aspirin or clopidogrel. Figure 1 outlines the use of warfarin and anti-platelet
medications in the 1767 residents with AF. As shown in Figure 2, 954 (54%) residents
with AF did not receive any form of antithrombotic therapy in the form of warfarin,
aspirin, clopidogrel or combination of these medications. Ticlopidine and dipyridamole
were not prescribed in any resident. Table 1 summarizes the demographics, risk factors
for stroke, residents CHADS2 score and potential risk factors for bleeding, stratified by
warfarin-users and non-users. Since the percentage of residents with hepatic failure was
<1% this variable was not included in the analysis. The percentages included in this table
are based on weighted frequencies calculated using the sampling weights provided and
are thus national estimates.
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Table 1: Characteristics of nursing home residents with atrial fibrillation, with
indications for and no contraindications to warfarin, stratified by warfarin use
Resident Characteristic

Age groups (years)
60-79
80-89
≥ 90
Sex
Male
Female
Race
White
Non-white
Ethnicity
Hispanic
Non-hispanic
Length of stay (days)
< 90
≥ 90
Total no. medications
0-5
6-15
16-30
Stroke Risk Factors†
Congestive heart failure
Hypertension
Diabetes mellitus
Previous stroke/ TIA
Coronary heart disease
DVTc/ peripheral
embolus
Valvular heart disease
CHADS2 score for stroke
risk†
0-1
2

	
  

Warfarin users
N=58,779 (31%)
%

Warfarin non-users
N=133,284 (69%)
%

p-valuea

22
53
25

20
45
35

0.0007*

28
72

30
70

0.5024

96
4

90
10

0.0021*

3
97

2
98

0.1785

24
76

22
78

0.3415

7
81
12

16
78
6

<0.0001*

40
63
24
34
31
8
4

35
61
23
24
30
3
2

0.0948*
0.5477
0.7505
0.0002*
0.7289
<0.0001*
0.0281*

40
27
26

50
26
19

0.0026*
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3
4-5
Bleeding risk factors†
History of GI bleeding
Dementia
Falls (past 31-180 days)
Myocardial infarction
CKD/ renal failure
Malignancy
Use of warfarininteracting
drugs:
(i)
Anti-platelets
(ii)
NSAIDs

	
  

	
  	
  	
  

7

5

4
6
29
2
27
4

7
5
28
3
26
6

4
13

24
10

0.0150*
0.2750
0.9570
0.3043
0.7479
0.2056

<0.0001*
0.0414*

† not mutually exclusive
a
p-value from chi-square analysis between warfarin users and non-users and resident
characteristics
*p-value significant at <0.10
TIA = transient ischemic attack; CKD = chronic kidney disease; NSAIDs = Nonsteroidal anti-inflammatory drugs; CHADS2 = congestive heart failure, hypertension, age
≥ 75 years, diabetes mellitus and prior stroke or transient ischemic attack
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Figure 1: Summary of use of warfarin and other anti-platelet medications in eligible
nursing home residents with atrial fibrillation
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Figure 2: Use of warfarin and other anti-platelet medications by nursing home
residents with atrial fibrillation (n = 1767)

Combination therapy includes (i) warfarin and aspirin (n=17) (ii) aspirin and clopidogrel
(n=20) (iii) warfarin and clopidogrel (n=4)

B. Factors associated with warfarin use
Table 2 presents the results of the multivariable analysis with the adjusted odds ratio
(OR), 95% CI and p-value for factors that were found to be significantly associated with
warfarin use. These factors include age, race, total number of medications, stroke risk
factors (CHF, previous stroke/ TIA, DVT/ peripheral embolism, and valvular heart
disease) and potential bleeding risk factors (history of GI bleeding and use of antiplatelets or NSAIDs).
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The association of age with warfarin use was such that residents in the ≥ 90 years age
group were less likely to be receiving warfarin as compared to the 60-79 years age group.
(OR=0.61, 95%CI = 0.44-0.85). Non-white residents had significantly lower odds for
receiving warfarin as compared to white residents (OR= 0.37; 95% CI = 0.22-0.63)).
With an increasing number of prescribed medications, residents were more likely to be
receiving warfarin, such that residents taking 6-15 and 16-30 medications were more
likely to be receiving warfarin as compared to those taking 0-5 medications (OR= 3.03,
95% CI = 2.03-4.50 and OR= 7.41 , 95% CI = 4.27-12.87 respectively). Among the
stroke risk factors, residents with CHF (OR=1.29, 95% CI=1.03-1.62), previous stroke
event/ TIA (OR=2.26, 95% CI=1.77-2.90), DVT (OR=5.83, 95% CI=3.18-10.70) and
valvular heart disease (OR=1.77, 95% CI=0.93-3.39) were more likely to be receiving
warfarin. The only potential bleeding risk factors for warfarin that was significantly
associated with warfarin use was history of GI bleeding and use of anti-platelets (i.e.
clopidogrel), such that residents with a prior GI bleeding event (OR = 0.51, 95%
CI=0.31-0.84) and those using anti-platelets (OR=0.10, 95% CI=0.06-0.17) were less
likely to be prescribed warfarin.
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Table 2: Factors associated with warfarin use in nursing home residents with atrial
fibrillation, with indications for and no contraindications to warfarin
Variable
Age
60-79
80-89
≥ 90
Race
White
Non-White
Total no. medications
0-5
6-15
16-30
Stroke risk factors
Congestive heart failure
Previous stroke/ TIA
DVT/ peripheral embolus
Valvular heart disease
Bleeding risk factors
History of GI bleeding
Use of anti-platelets

V.

Adjusted Odds Ratio (95% CI)

p-value

1.00
1.05 (0.79 – 1.41)
0.61 (0.44 – 0.85)

0.0001

1.00
0.37 (0.22– 0.63)

0.0003

1.00
3.03 (2.04 – 4.52)
7.44 (4.28 – 12.93)

<0.0001

1.29 (1.03 – 1.63)
2.26 (1.76 – 2.89)
5.83 (3.17 – 10.70)
1.76 (0.92 – 3.37)

0.0275
<0.0001
<0.0001
0.082

0.48 (0.30 – 0.78)
0.10 (0.06 – 0.17)

0.0031
<0.0001

Discussion

A. Underuse of warfarin in NH residents:
The results of this cross-sectional analysis showed that 14% of all NH residents had a
diagnosis of AF and 13% of all NH residents had a diagnosis of AF with indications for
and without contraindications to warfarin use, of which about 30% received
anticoagulation therapy with warfarin. Furthermore, about 23% of residents who did not
receive warfarin, received secondary stroke prophylaxis with either aspirin or
clopidogrel. Thus 54% of NH residents did not receive either warfarin or antiplatelet
therapy with aspirin or clopidogrel. It was not surprising that none of the residents
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received ticlopidine, since the use of this agent is discouraged in older adults.(10)
Previous studies have found the prevalence of AF in NH residents to be around 7.5-17%;
however, these studies were done more than 10 years ago.(14-16) The 30% rate of
warfarin use in NH residents reported in this study was similar to what has been reported
previously for NH residents. Gurwitz et al. reported that 32% of patients with AF were
being treated with warfarin across 30 long-term care (LTC) facilities,(15) McCormick et
al. reported 42% warfarin use in NH patients with AF(16) and Lackner et al. reported that
only 20% of NH patients with nonvalvular AF were being treated with warfarin as per the
ACCP guidelines.(14) Similar to these studies the results of this cross-sectional analysis
suggest that anticoagulation therapy with warfarin or anti-platelet therapy with aspirin or
clopidogrel may be underused in this nationally representative sample of NH residents.

Major practice guidelines, such as those by the American College of Chest Physicians
(ACCP), the American Heart Association/ American Stroke Association and American
College of Cardiology/ American Heart Association recommend warfarin as a class I
recommendation for stroke prevention in patients with AF. (3-5) Furthermore, the ACCP
guidelines have been adapted for use in older adults by the American Geriatrics Society
and their recommendations also include the use of warfarin for prevention of stroke in
patients with nonvalvular AF and without a contraindication to warfarin.(52) Thus in
spite of these practice guidelines, underuse of warfarin is consistently being reported for
older adults, not only in NH residents but also in community dwelling and hospitalized
older adults.(34, 53-55) Safety of warfarin therapy in NH residents may be a cause of
concern, leading to its underuse. A study done in 25 NHs by Gurwitz et al. found that
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87% of all the 720 warfarin-related adverse events were minor, 11% were deemed serious
and 2% were considered life-threatening or fatal.(28) Furthermore, 29% of adverse
warfarin-related events were deemed preventable in NH settings.(28)
There may be several barriers to prescribing warfarin and these may be classified as
patient, physician and health care system-related barriers.(56) Important patient-related
barriers included increasing age, perceived embolic risk and perceived risk for
hemorrhage and the most important and consistent physician-related barrier was the
physician’s perception of the benefit vs. risk of therapy.(56) A survey that assessed the
attitude of LTC physicians towards warfarin use showed that 34% of the physicians
believed the benefits of warfarin only slightly outweighed the risks, and 19% believed
that the risks outweigh the benefits.(57) Future research may help to determine whether
these barriers relate to possible warfarin underuse in NH residents.

The patterns of anti-coagulation use in NH settings for patients with AF may change with
the newly approved oral anticoagulant, dabigatran. Since this medication was recently
approved, little is known about the patterns of use and safety profile associated with
dabigatran in the NH setting. Some features that may seem attractive for use of
dabigatran are fixed doses, renal excretion and no monitoring of INR required.(58) In
addition, dabigatran may be more expensive but would have lower costs associated with
monitoring the patient.(59) However, lack of monitoring of older adults on
anticoagulation therapy, especially frail nursing home residents, may be a cause of
concern given the risks associated with anticoagulation therapy in general. Two cases of
dabigatran-related adverse events were recently reported in 2 older frail women, from
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which one had a fatal outcome.(60) Both women had low body weight and reduced renal
function. Thus LTC physicians may need to be cautious while prescribing dabigatran to
frail patients with moderate or severe renal insufficiency until there is more data available
regarding its use in older adults. It would be interesting to know from future studies
whether LTC physicians have started prescribing dabigatran to NH residents with AF,
and how these prescribing patterns affect the possible underuse of anticoagulation in NH
settings. Given the long track record of warfarin usage and knowledge about its potential
adverse effects, it may be possible that LTC physicians would want to continue warfarin
therapy for patients that are already stable on it.

B. Factors associated with warfarin use:
Residents aged 90 years and above were less likely to receive a prescription for warfarin
as compared to those in the 60-79 year age group. Previous studies have also reported
older age, usually ≥85 years, to be a predictor of warfarin underuse.(61-63) There is
evidence to support an increased bleeding risk in patients >80 years.(64) Fear of
increased bleeding risk, frailty and increased risk for falling may have led to a decreased
use of warfarin in the oldest resident age group. This may raise a particular concern for
warfarin therapy in those aged ≥ 90 years and above since older patients appear to be at
the highest risk of ischemic stroke if not treated and have the highest absolute reduction
in risk of ischemic stroke when treated.(65) Thus the oldest patients who are more likely
to need and benefit from warfarin therapy are also at higher risk of warfarin-related
bleeding events. Residents of the non-white race were less likely to receive warfarin as
compared to whites. This kind of a racial difference in warfarin use has been shown in

	
  

80	
  

	
  
	
  
	
  
	
  
previous studies as well.(11, 49) Residents using 6-15 or 16-30 total number of
medications were more likely to be prescribed warfarin than those receiving 0-5
medications. This association may have important implications since warfarin is known
to undergo interactions with several medications.(66) A study that assessed the use of
warfarin-interacting medications in long-term care found that 79% of NH residents were
prescribed at least one warfarin-interacting medication and these residents were found to
spend significantly less time in the therapeutic range.(67) Future studies could provide
more information on what percentage of these medications may be potentially interacting
with warfarin. As expected, residents with stroke risk factors such as CHF, previous
stroke/ TIA, DVT/ PE and VHD were more likely to receive warfarin as a measure for
stroke prophylaxis. While history of stroke or TIA has consistently been reported as a
predictor of warfarin use, the results for the other stroke risk factors have varied across
studies.(35, 62, 63) The finding that CHADS2 score was not part of the final logistic
model in spite of it being an important predictor of stroke risk may seem unusual. A
possible reason for this may be that most of the variables comprising this index were
already inputted as independent predictors in to the logistic model. Two of these
CHADS2 variables, CHF and prior stroke/ TIA were found to be significant predictors of
warfarin use. Thus due to reasons of collinearity of the CHADS2 score with other
variables, it may not have been significant in the final model. Of all the potential bleeding
risk factors that were included in this study, only history of GI bleeding and use of antiplatelets was associated with a decrease in warfarin use. History of GI bleeding has been
found to be a significant predictor in previous studies.(35, 61, 62) It seems logical that
residents receiving warfarin were less likely to be prescribed anti-platelets (i.e.
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clopidogrel) since these residents with AF are already receiving anticoagulation therapy.
A secondary reason may be the fear of warfarin-clopidogrel drug interaction. On the
other hand, there were no significant differences in NSAIDs prescriptions among
warfarin users and non-users.

Based on the results of this study, the use of warfarin could be potentially increased in
some ways. If fear of bleeding events is a concern for those above the age of 90 years,
use of some of the bleeding risk scores such as HEMOR2RHAGES, HAS-BLED or the
Outpatient bleeding risk Index, in conjunction with the stroke risk index, such as
CHADS2 may help to assess the risk versus benefits of warfarin therapy.(37, 40, 68, 69)
Interventions to increase the use of warfarin in the minority NH population could be
implemented. Suboptimal effectiveness and less frequent monitoring of warfarin among
black and Hispanic Medicare beneficiaries as compared to whites have been shown in a
previous study.(11) In addition, genetic polymorphisms may affect the sensitivity of
warfarin and are known to vary in prevalence according to race.(11) Thus possible
reasons for underuse of anticoagulation therapy in non-whites could be an area of future
research. If suboptimal effectiveness, lower monitoring and genetic polymorphisms are
found to be potential reasons for decreased warfarin use in non-whites, alternate
strategies for anticoagulation, such as dabigatran, could be employed for these patients.
Some limitations of this study may be identified. Due to the nature of the data we could
not confirm the diagnosis of AF clinically by means of an electrocardiogram and whether
residents had paroxysmal, persistent or permanent AF. It was also not possible to know
if patient was actively in AF or had been successfully cardioverted. Since patients go in
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and out of AF, it is difficult to know if they are currently in AF at the time of assessment
from the survey. Data on the type of medication order (i.e. standing, routine, or PRN),
dosage, strength, route, or frequency information was not collected. The accuracy of
stroke/ TIA codes (434-436) reported by some studies was poor.(42, 45) Determining
‘suitable’ ICD-9-CM codes to identify subjects of interest in epidemiological studies such
as this will always be a shortcoming. One way of accounting for this limitation is to
restrict the analysis to ICD-9 codes that have been used frequently in prior studies,(41,
49, 50) and codes with acceptable levels of sensitivity, specificity and positive predictive
values (PPVs). Stroke and stroke risk factors such as atrial fibrillation, coronary artery
disease, diabetes mellitus and hypertension have been coded with sensitivity from 81% to
91% and specificity ranging from 83% to 100%.(33)The potential bleeding risk factors
and stroke risk factors included only those variables for which data were collected in the
NNHS. Information on additional bleeding risk factors, such as vascular malformation,
uncontrolled hypertension, seizure disorders, fluctuating INR values and pharmacokinetic
drug interactions, or stroke risk factors such as left atrial size > 45mm and left ventricular
ejection fraction <40% or contraindications to warfarin use such as planned surgery
within a month, chronic alcohol abuse, poor compliance, patient refusal of warfarin and
warfarin allergy was not available. In addition, there was a lack of knowledge regarding
previous warfarin use. A resident may have been on warfarin in the past but may have
been discontinued from it for reasons that were not captured in the survey. However, the
analysis included all available stroke and bleeding risk factors to determine residents with
AF who should potentially be receiving warfarin. Additionally, the validity of coding of
warfarin and antiplatelets medications in the LTCDDS is not routinely checked. The

	
  

83	
  

	
  
	
  
	
  
	
  
information on medications used by the resident is collected based on review of the
medication administration record. Since this is supposed to be the record of actual
medication administration, we would expect it to be valid; however, there may be some
error and this is a known limitation of this type of data. According to the NNHS, history
of falls was defined as those who ‘fell in past 31-180 days’. Thus this definition does not
include residents who had a fall prior to 180 days or within 31 days from the time of the
survey, suggesting that the percentage of those with falls may have been higher than what
was actually reported in this analysis. Since this was a cross-sectional analysis it was not
possible to determine whether residents who did not receive anticoagulation were more
likely to have adverse stroke or thromboemobolic outcomes as compared to those who
received stroke prophylaxis. Finally, due to the cross-sectional nature of the study it is not
possible to make any causal inferences for the factors associated with warfarin use. Thus
the term ‘predictors’ was avoided for any of the factors that were found to be
significantly associated with warfarin use. The study provided the prevalence of AF and
warfarin use in NH residents at one point in time; the results may differ if another time
frame had been chosen given the new oral anticoagulant, dabigatran that was recently
approved in 2010. However, the 2004 NNHS survey was the mostly recent wave of the
survey and no other study has recently determined these national prevalence estimates of
AF for NH residents. These rates were not comparable to previous estimates of the
NNHS since this was the first time in the survey’s history that medication data was
collected.
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VI.

Conclusion

The overall prevalence of AF in NH residents was 14%, such that 13% of the total
number of residents had a diagnosis for AF with indications for and no contraindications
to warfarin use. The total rate of warfarin use in these residents with AF was about 30%,
confirming the results of previous studies that suggest an underuse of warfarin in NH
residents with AF. Age ≥ 90 years, non-white race, total number of medications, CHF,
previous stroke/ TIA, DVT/ PE, VHD, GI bleeding history and use of anti-platelets were
factors that were significant predictors of warfarin use. Suggestions for future research
include development of effective strategies to impact anticoagulation prescribing patterns
in order to ensure that NH residents most likely to benefit from anticoagulation therapy
are actually receiving it. Furthermore, it would be interesting to know whether a change
in anticoagulation prescribing patterns in NH residents would lead to improved patient
outcomes in terms of reduced stroke rates and reduced adverse bleeding outcomes.
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CHAPTER 4
Warfarin-Antibiotic Interactions in Older Adults of an
Outpatient Anticoagulation Clinic
I. Abstract
Background: Several drugs may interact with warfarin to cause an increase in its
anticoagulant activity. There are conflicting reports on the nature of warfarin-antibiotic
interactions and data on outcomes of over-anticoagulation associated with warfarinantibiotic interactions is limited in older patients
Objective: To determine the effect of oral antibiotics, such as amoxicillin, azithromycin,
cephalexin, ciprofloxacin, levofloxacin and moxifloxacin, on the international normalized
ratio (INR) in patients on stable warfarin therapy, aged 65 years or above, and to
determine and compare the effect of warfarin-antibiotic interactions on secondary
outcomes of over-anticoagulation.
Methods: This is a retrospective cohort study utilizing data from a medical record review
of patients from an outpatient anticoagulation clinic at a Veterans Affairs medical center.
Patients aged 65 years or above, who were on stable warfarin therapy and received a
prescription of the antibiotics of interest, during the period from January 1st, 2003 to
March 1st, 2011, were included. Depending on the availability of INR values in the
anticoagulation clinic notes, two INR values were recorded before antibiotic start date,
i.e. pre-antibiotic INR 1 and 2, and two INR values were recorded after start of antibiotic,
i.e. post-antibiotic INR 1 and 2. Mixed-effects repeated measures ANOVA model was
used to determine the effect of antibiotics on the mean change in patient’s INR over these
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four periods of time. The secondary outcomes of interest were percentage of patients
whose warfarin dose was adjusted/ withheld, INR > therapeutic, INR increase >1, INR
increase >2, absolute INR ≥ 4 or ≥ 5, vitamin K administration or major/ minor bleeding
events. The Fisher’s exact test was used to test whether there was an association between
the type of antibiotic and the above secondary outcomes of over-anticoagulation, using
cephalexin as the control. Statistical significance was defined as a p-value of < 0.05. All
analyses were done using SAS 9.2 (SAS Institute Inc, Cary, NC, USA).
Results: There were 364 prescriptions of warfarin-antibiotics in a total of 205 patients
during the study period. The ANOVA model indicated that there was a significant
interaction between antibiotic and time (F (15, 358) = 1.9); p-value=0.0221). There was a
significant increase in INR values from time point 2 to 3 for amoxicillin (p=0.0019),
azithromycin (p<0.0001), ciprofloxacin (p=0.002), levofloxacin (p<0.0001) and
moxifloxacin (p<0.0001). There was no significant increase in INR for cephalexin
between time point 2 and 3 (p=0.2807). The Fisher’s exact test indicated that there was a
significant association between the type of antibiotic and secondary outcomes. Overall,
the percentage of patients with warfarin dose withheld, INR > therapeutic, INR increase
> 1, were significantly greater in the azithromycin, ciprofloxacin, levofloxacin and
moxifloxacin group as compared to cephalexin (p<0.05 for all antibiotics). No bleeding
events were reported in any of the patients.
Conclusion: Amoxicillin, azithromycin and fluoroquinolone antibiotics such as
ciprofloxacin, levofloxacin and moxifloxacin, lead to a significant increase in INR values
post-antibiotic use in older patients, when taken concomitantly with warfarin. However,
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this increase in post-antibiotic INR did not lead to clinically significant outcomes of
bleeding or hospitalization. Thus antibiotics may be prescribed to older adults on
warfarin therapy; however, increased INR monitoring may be required to ensure the INR
remains within therapeutic range during the course of antibiotic therapy.
Keywords: Warfarin, antibiotics, drug interactions, older adults
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II. Introduction

Warfarin is the most widely used oral anticoagulant and its use is the highest in older
adults due to the increased prevalence of conditions such as atrial fibrillation and other
thromboembolic disorders with advancing age.(1) Warfarin therapy may be complicated
by several factors and maintaining therapeutic levels of warfarin is challenging since it is
a drug with a narrow therapeutic index and it exhibits considerable variability in dose
response.(2) Several medications may undergo a pharmacokinetic or pharmacodynamic
interaction with warfarin, thus increasing the risk of adverse outcome of overanticoagulation. Drug interactions with warfarin were ranked at number 3 in a list of the
top 30 adverse events reported for warfarin in the FDA’s Adverse Events Reporting
system, for the period from June 2003 to July 2006.(3) The most recent systematic review
on warfarin-drug interactions recommends exercising caution while prescribing
antibiotics to patients on warfarin, since antibiotics may cause a change in the patient’s
hematological response to warfarin.(4) The antibiotic classes that were listed include
fluoroquinolones, macrolides, tetracyclines and penicillins. From the list of top 10
dangerous drug interactions in nursing home residents, developed by the American
Society of Consultant Pharmacists as one of the initiatives of their Multidisciplinary
Medication Management Program, 5 of these interactions involved warfarin and 3 of
these were due to warfarin-antibiotic combinations such as sulfa drugs, macrolides and
quinolones.(5)
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The risk of an interaction may be higher in older adults due to age-related physiologic
changes that may result in altered pharmacodynamic response for warfarin,(6) and altered
pharmacokinetics of antibiotics, such as fluoroquinolones.(7) However, the literature fails
to support the increased risk of bleeding events or over-anticoagulation with warfarinantibiotic combinations.(8) Some of these studies were done in settings with close
anticoagulation monitoring. However, if there was no dose reduction or holding of doses
the risk of complications may be higher. The most recent review that evaluated the
possibility of increased anticoagulation due to warfarin-quinolone interactions concluded
that “there are no consistent data to support the claim of an increased anticoagulation
response in patients receiving warfarin and any of the three commonly prescribed
fluoroquinolones”.(9) The clinical evidence for warfarin-antibiotic interactions in older
adults is very limited and most of the evidence comes from case reports and case
series,(10-13) or from studies with very few subjects.(14-17)

Due to the conflicting nature of the reports on warfarin-antibiotic interactions and lack of
studies done specifically in older patients, there is a need to understand the clinical
relevance of warfarin-antibiotic interactions in older adults. The primary objective of the
study was to determine the effect of antibiotics on INR values over time in patients on
stable warfarin therapy from an outpatient warfarin clinic. The secondary objective was
to determine and compare the effect on secondary outcomes of over-anticoagulation
caused by the combination of warfarin-antibiotics since this may further help us to
understand the potential clinical impact of supratherapeutic INR values due to warfarinantibiotic interactions.
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III. Methods
A. Study Setting

This study was conducted at the Hunter Holmes McGuire Veterans Affairs (VA) medical
center, Richmond, VA, using data from the outpatient anticoagulation clinic. The study
protocol was approved by the Richmond Veterans Affairs institutional review board
(IRB) and the Virginia Commonwealth University IRB in January 2011. Due to the
retrospective nature of the study, informed consent was waived.

B. Study Design and Patients
This was a single-center, retrospective review of medical and pharmacy records of
patients aged 65 years and above, who received a prescription of warfarin and either
amoxicillin, azithromycin, cephalexin, ciprofloxacin, levofloxacin or moxifloxacin,
concomitantly from January 1, 2003 to March 1, 2011. Patients that were included were
aged 65 years and above and were on stable warfarin therapy, defined as pre-antibiotic
INR values within ± 0.2 of recommended therapeutic INR range during the 4-week
period before the antibiotic start date. This would eliminate patients with fluctuating INR
values. In the presence of 2 or more pre-antibiotic INR values, all INR values were
recorded. Patients must also have had at least one INR value recorded during their
antibiotic therapy or during the 14-day period after discontinuation of the antibiotic (i.e.
post-antibiotic INR) in order to be included. In addition, patients must have had a
prescription of the antibiotic for 3 days or more in order to be included.
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Patients were excluded if there was a change in their warfarin dose from the date their
pre-antibiotic INR was recorded to the date of starting their antibiotic prescription or if
there was a change in the patient’s warfarin dose after the antibiotic start date and before
the post-antibiotic INR value was recorded. Patients were excluded if they did not have
an anticoagulation clinic note before and after the period of starting the antibiotic.
Without a clinic note it would not be possible to ascertain whether patients were on stable
warfarin therapy, were compliant to therapy or to gather information on other
concomitant interacting medications that the patient may have been prescribed. Patients
that were not compliant to warfarin therapy were excluded since non-compliance may
lead to fluctuating INR values. Patients undergoing a dental procedure were not included
because antibiotics are usually given prophylactically for these patients and may be
prescribed as a one-time course of one day. These patients may also not be the same as
the other study patients with an active infection. Patients receiving enoxaparin (LMWH)
concomitantly with warfarin were excluded since this may further complicate
anticoagulant activity. Finally, patients were excluded if they received a prescription for
other potentially interacting medications during the period from the last pre-antibiotic
INR measurement and the first post-antibiotic INR measurement. The potentially
interacting medications that patients were screened for in this study included,
amiodarone, metronidazole, trimethoprim-sulfamethoxazole, carbamazepine, phenytoin,
fluconazole, ketoconazole, rifampin, isoniazid, prednisone and phenobarbital, since they
are known to have a well-documented interaction with warfarin.(4) Patients newly
initiated on amiodarone were not included since a warfarin dose reduction of 20-50% is
generally done for these patients.

	
  

103	
  

	
  	
  	
  

	
  
	
  
	
  

	
  
C. Data Collection

A list of patients meeting the inclusion criteria was electronically generated. The
electronic medical recording system of the VA, known as the Computerized Patient
Record System (CPRS), was used to collect patients’ demographic data, such as age, sex
and race; prescription data such as warfarin and antibiotics dose, duration of use, and
indications for use, warfarin dose adjustments, vitamin K administration; laboratory data
such as target INR range, pre- and post-antibiotic INR values and other medical data such
as number of concomitant medications and disease conditions, interacting medications
(as listed above), bleeding events, hospitalizations, or emergency department visits. Data
were entered and stored in a secure, password-protected computer.

D. Outcome Measures
The outcomes of interest for the primary analysis were the post-antibiotic INR values.
Pre-antibiotic INR values were collected during the 4-week period before start of the
antibiotics. All INR values during this period were recorded as long as they were within ±
0.2 of the therapeutic INR range. Thus pre-antibiotic INR values were defined as the
most recent INR values collected in the 4-week period before start of the antibiotic
therapy. Post-antibiotic INR values were collected during the duration of use of the
antibiotic or during the 14-day period following the discontinuation of antibiotic therapy.
All available INR values during this period were recorded. Thus post-antibiotic INR
values were defined as all INR values available after start of the antibiotic up to 14-days
after discontinuation of the antibiotic therapy.
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The secondary outcomes of interest were percentage of patients whose warfarin dose was
adjusted (reduced or withheld); INR > therapeutic; INR increase >1, or INR increase > 2;
absolute INR ≥ 4, or absolute INR ≥ 5; vitamin K administration; minor or major
bleeding events; hospitalizations or emergency department visits. Cephalexin was chosen
as a comparator drug to compare the percentages of patients with the above secondary
outcomes of over-anticoagulation to the percentages of patients with the above outcomes
for the amoxicillin, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin groups.
There were several reasons for choice of cephalexin as a comparator drug. More than
90% of cephalexin is excreted unchanged renally and does not undergo metabolism via
hepatic CYP2C9 pathways.(18) Thus pharmacologically cephalexin would not have the
potential to interact with warfarin since it would not inhibit warfarin metabolism.
According to the consensus of clinical opinion, cephalexin is not known to interact with
warfarin.(19) Standard drug-drug interaction compendia and systematic reviews of
warfarin drug interactions do not classify cephalexin as a warfarin-interacting
medication.(4) One way of reducing confounding by indication is to use a control drug
that has similar prescription indications as the other antibiotics. Cephalexin has similar
indications as the other antibiotics in this study.(20) Cephalexin is used to treat
respiratory tract infections, otitis media, skin and skin structure infections, bone infection
and genitourinary tract infections. Thus use of a control drug with similar indications will
help to ensure that all patients being compared have an active infection.
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E. Statistical Analysis

Continuous data are presented using means, SD and ranges. Categorical baseline data are
presented as frequencies and percentages. Mixed-effects repeated measures ANOVA
model was used to determine the effect of antibiotics on the mean change in patient’s
INR over time. Statistical significance was defined at an alpha level of 0.05. The changes
in INR values between time point 2 (i.e. pre-antibiotic INR 2) and time point 3 (i.e. postantibiotic INR 1) for each antibiotic were of interest (i.e. 6 comparisons). In addition, the
change in INR values at time points 3 (i.e. post-antibiotic INR 1) between each antibiotic
was also of interest (i.e.15 comparisons). Thus there were a total of 21 comparisons of
interest. A Bonferroni adjustment of the alpha level was done to account for these
multiple comparisons (adjusted alpha = 0.05/21 = 0.0023).

A chi-square test or Fisher’s exact test, where appropriate, was done to test whether there
was an association between the type of antibiotic and the secondary outcomes of overanticoagulation. The percentage of patients with the secondary outcomes of overanticoagulation i.e., INR increase ≥ therapeutic, INR increase ≥ 1, INR increase ≥ 2,
absolute INR ≥ 4, absolute INR ≥ 5 and warfarin dose adjustment, with azithromycin,
amoxicillin, ciprofloxacin, levofloxacin and moxifloxacin were compared with those on
cephalexin. All analyses were done using SAS 9.2.
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IV. Results

A total of 205 patients received 364 prescriptions for the antibiotics of interest
concomitantly while on warfarin therapy, such that there were 96 prescriptions for
amoxicillin, 73 prescriptions for azithromycin, 49 prescriptions for cephalexin, 64
prescriptions for ciprofloxacin, 28 prescriptions for levofloxacin and 54 prescriptions for
moxifloxacin during the time frame of the study. The mean age of the patients was 75.7
(SD = 6.7) years and the median age was 75.5 (interquartile range = 70-81) years. The
mean pre-antibiotic INR values for patients ranged from 2.3 to 2.5 (SD = 0.4- 0.5) across
the six antibiotics. The baseline demographic characteristics of the patients are shown in
Table 1. The population primarily consisted of white males and the two most common
indications for warfarin use were atrial fibrillation and deep vein thrombosis.

The ANOVA model indicated that there was a significant interaction between antibiotic
and time (F (15, 358) = 1.9; p-value = 0.0221). These results indicate that the pattern of
INR changes for the 6 antibiotics are significantly different across time. The mean change
in INR from pre-antibiotic INR value 2 to post-antibiotic INR value 1, for each of the six
antibiotics is shown in Table 2. This mean INR increase was significant for amoxicillin
(0.31 ± 0.10, p=0.0019), azithromycin (0.60 ± 0.11, p <0.0001), ciprofloxacin (0.38 ±
0.12, p=0.002), levofloxacin (0.75 ± 0.18, p <0.0001) and moxifloxacin (0.70 ± 0.13, p <
0.0001). There was no significant increase in INR for cephalexin between time point 2
and 3 (p=0.2807). This trend of change in INR values over time for each antibiotic is
shown in Figure 1. Additionally, at time point 3 there were no significant differences in
post-antibiotic INR values between the six different antibiotics.
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The frequency and percentages of patients experiencing the secondary outcomes of overanticoagulation for each antibiotic group are shown in Table 2. The percentage of
patients who had a warfarin dose adjustment (either withheld or reduced) was the highest
for levofloxacin (25%), followed by moxifloxacin (24%), ciprofloxacin (17%) and
azithromycin (12%). The Fisher’s exact test indicated that these percentages were
significantly higher (p<0.05) for the fluoroquinolone antibiotics and azithromycin as
compared to cephalexin (2%). The percentages and p-values were computed from the
Fisher’s exact test using a separate 2x2 table for the comparison of each antibiotic group
with the cephalexin group. For increase in INR above therapeutic range, the percentage
of patients was significantly higher (p<0.05) for azithromycin (41%), levofloxacin (46%)
and moxifloxacin (40%) as compared to cephalexin (16%). For an increase in INR by
more than one point, the percentages of patients were significantly higher (p<0.05) for
azithromycin (23%), ciprofloxacin (20%), levofloxacin (36%) and moxifloxacin (31%) as
compared to cephalexin (4%). Finally, the percentage of patients with absolute INR ≥ 4
was significantly higher (p<0.05) for the moxifloxacin group (15%) as compared to
cephalexin (2%). There were no reports of major or minor bleeding events;
hospitalizations or emergency department visits during concomitant warfarin antibiotic
therapy.

Additional post-hoc analyses were done to explain the effect of infection and the effect of
increasing age on INR changes. To test for the effect of infection, mean change in INR
from pre- to post-antibiotic use was determined separately by type of infection for all
fluoroquinolones (ciprofloxacin, levofloxacin and moxifloxacin) and azithromycin.
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(There were not sufficient patients for this analysis in the other antibiotic groups). The
results of the repeated-measures ANOVA model indicated that for the fluoroquinolone
group the mean increase from pre- to post-antibiotic INR was significant for all patients
with a lower respiratory tract infection (0.8 ± 0.2; p = 0.0007) or a urinary tract infection
(0.4 ± 0.1; p=0.0132) but was not significant for patients with a skin or soft tissue
infection (0.5 ± 0.3; p =0.3870). For the azithromycin group the mean increase in INR
was significant for patients with lower respiratory infections (0.7 ± 0.1; p <0.0001) and
for those with upper respiratory infection (0.5 ± 0.1; p=0.0103). These results are shown
in Table 3.

Furthermore, to test for the effect of increasing age, the mean change in post-antibiotic
INR were compared for the lower age quartile (i.e. patients aged 65-70 years) and upper
age quartile (i.e. patients aged ≥ 81 years). For the first recorded mean post-antibiotic
INR value there was no difference between the lower and upper quartiles of age (mean
difference in INR=0.10 ± 0.13; p=0.3783). However, for the second recorded postantibiotic INR values, the mean INR value was significantly greater in the upper age
quartile, i.e. patients aged ≥ 81 years, as compared to the lower age quartile, i.e. patients
aged 65-70 years (mean difference in INR= 0.70 ± 0.25; p=0.0036). These results are
shown in Table 4. Additionally, Table 5 provides details of patients with an INR ≥ 4,
such as dosage and duration of antibiotic, type of infection, pre- and post-antibiotic INR
and warfarin dose adjustments, after start of the antibiotic.
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Table 1: Baseline demographic and clinical characteristics of study patients

Characteristic
Mean Age, years
Median (IQR), years
Pre-antibiotic INR 1
Pre-antibiotic INR 2
Duration of antibiotic use, days
Total number of medications
Total number of disease conditions
Males
Race (white)
Indication for warfarin use
Atrial fibrillation/ Atrial flutter
DVT/ PE
Mechanical valve replacement
Other
Indication for antibiotic use
Lower respiratory infections (LRI)
Upper respiratory infections (URI)
Urinary tract infections (UTI)
Skin & soft tissue infection (SSTI)
Other

	
  

Amoxicillin Azithromycin Cephalexin
(N = 96)
(N = 73)
(N = 49)
Mean (SD)
75.3 (6.6)
74.1 (6.7)
75.4 (6.1)
74 (71-80)
74 (68-80)
75 (70-79)
2.4 ± 0.4
2.4 ± 0.5
2.4 ± 0.4
2.4 ± 0.4
2.4 ± 0.4
2.5 ± 0.4
10 (2)
6 (3)
11 (6)
11 (4)
11 (4)
11 (4)
12 (5)
12 (5)
12 (6)
No (%) of Patients
95 (99)
73 (100)
48 (98)
78 (81)
53 (73)
38 (78)

Ciprofloxacin Levofloxacin Moxifloxacin
(N = 64)
(N = 28)
(N = 54)

75 (78)
13 (14)
2 (2)
6 (6)

63 (86)
10 (14)
-

16 (17)
19 (20)
17 (18)
33 (34)
11 (12)

35 (48)
35 (48)
1 (1)
2 (3)
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76.6 (6.5)
77.5 (71-81)
2.3 ± 0.4
2.5 ± 0.4
14 (10)
11 (5)
12 (5)

79 (7.2)
82 (73-85)
2.4 ± 0.4
2.4 ± 0.4
9 (6)
12 (5)
13 (5)

75.7 (6.6)
76 (71-81)
2.4 ± 0.5
2.3 ± 0.4
9 (5)
12 (5)
13 (6)

63 (98)
42 (66)

28 (100)
16 (57)

53 (98)
40 (74)

39 (80)
6 (12)
2 (4)
2 (4)

47 (74)
5 (8)
2 (3)
10 (16)

19 (68)
8 (29)
1 (4)
-

46 (85)
5 (9)
1 (2)
2 (4)

1 (2)
3 (6)
40 (82)
5 (10)

1 (2)
1 (2)
43 (67)
2 (3)
17 (27)

4 (14)
1 (4)
18 (64)
3 (11)
2 (7)

34 (63)
12 (22)
2 (4)
6 (11)
-

Table 2: International normalized ratio changes and secondary outcomes of over-anticoagulation

Variable
INR change (from pre-antibiotic
INR 2 to post-antibiotic INR 1)
Mean (SE)

Amoxicillin
(N = 96)

Cephalexin
(N = 49)

0.31 ± 0.10* 0.60 ± 0.11*
0.15 ± 0.14
No. (%) of patients

Intervention
Warfarin dose withheld
9 (9)
Secondary outcomes of overanticoagulation
INR > therapeutic
25 (26)
INR increase > 1
15 (16)
INR increase > 2
3 (3)
Absolute INR ≥ 4
6 (6)
Absolute INR ≥ 5
1 (1)
* p-value < 0.023 Bonferroni adjusted alpha-level
**
p-value < 0.05 versus cephalexin
†
p-value < 0.01 versus cephalexin
‡
p-value < 0.0001 versus cephalexin	
  

	
  

Azithromycin
(N = 73)

Ciprofloxacin Levofloxacin Moxifloxacin
(N = 64)
(N = 28)
(N = 54)

0.38 ± 0.12*

0.75 ± 0.18*

0.70 ± 0.13*

9 (12)**

1 (2)

11 (17)†

7 (25)†

13 (24)†

30 (41)†
17 (23)†
5 (7)
7 (10)
-

8 (16)
2 (4)
1 (2)
1 (2)
-

20 (31)
13 (20)**
4 (6)
5 (8)
1 (2)

13 (46)†
10 (36)‡
2 (7)
3 (11)
1 (4)

22 (40)†
17 (31)‡
6 (11)
8 (15)**
-
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Figure 1: Least squares means plot of change in INR values over time for different
antibiotics

(INR = International Normalized Ratio)
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Table 3: International normalized ratio changes by type of indication for antibiotic
use
INR change, from pre-antibiotic INR 2
to post-antibiotic INR 1
Type of Infection
Fluoroquinolones Azithromycin
(N = 146)
(N = 73)
1. Lower respiratory tract infection (LRI)
0.8 ± 0.2*
0.7 ± 0.1*
2. Upper respiratory tract infection (URI)
0.5 ± 0.1*
3. Urinary tract infection (UTI)
0.4 ± 0.1*
4. Skin and soft tissue infection (SSTI)
0.5 ± 0.3
*Denotes significant increase in INR from pre-antibiotic INR 2 to post-antibiotic INR
from the ANOVA model
Table 4: Mean INR values and change in INR values for subjects in the upper and
lower age quartiles
N

Mean INR
N
Mean INR Difference p-value
(65-70 yrs)
(≥ 81 yrs)
in INR
Pre-antibiotic INR 1 37 2.3 ± 0.4
37 2.5 ± 0.4
0.20 ± 0.10
0.1198
Pre-antibiotic INR 2 95 2.4 ± 0.4
98 2.4 ± 0.4
0.02 ± 0.06
0.7385
Post-antibiotic INR 1 95 2.9 ± 0.9
98 3.0 ± 1.0
0.10 ± 0.13
0.3783
Post-antibiotic INR 2 10 2.7 ± 0.6
18 3.5 ± 0.8
0.70 ± 0.25
0.0036*
* Denotes that the upper age quartile (i.e. ≥ 81 years) has significantly greater mean INR
values at time point 4 as compared to lower age quartile (i.e. 65-70 years) at a Bonferroni
adjusted significance level of 0.0125.
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Table 5: Details of patients with an absolute INR ≥ 4 after antibiotic use
Age
(yrs),
sex

Warfarin
Indication

Antibiotic

83, M
84, M

Afib
Afib

Moxifloxacin
Moxifloxacin

67, M
69, M
82, M
66, M
65, M

DVT/ PE
DVT/ PE
Afib
Afib
Afib

Cephalexin
Levofloxacin
Moxifloxacin
Moxifloxacin
Moxifloxacin

76, M
69, M
85, M
85, M

Afib
Afib
Afib
Aflutter

Azithromycin
Ciprofloxacin
Levofloxacin
Moxifloxacin

69, M

Afib

Azithromycin

83, M

MVR

Ciprofloxacin

77, M

Afib

Azithromycin

74, M
73, M
80, M

Afib
Afib
Afib

Azithromycin
Moxifloxacin
Amoxicillin

	
  

Antibiotic Dosage
and Duration

Antibiotic
Indication

Preantibiotic
INR

400mg qd x 14 days
400mg qd x 8 days
500mg four times x
7 days
250mg qd x 7 days
400mg x 14 days
400mg qd x 5 days
400mg qd x 7 days
500mg x 1 day,
250mg x 4 days
750mg qd x 10 days
250mg qd x 7 days
400mg qd x 10 days
500mg x 1 day,
250mg x 4 days

Pneumonia
Pneumonia

2.4
2.7, 2.6

4.6, 5.5
4.6

16
14

Yes
Yes

Cellulitis
UTI
Skin infection
Pneumonia
Pneumonia

2.4, 2.9
2.8
1.9, 2
3.2, 2.9
1.7, 1.8

5.4
4.3
5.5
6.4
5.4

16
24
11
3
7

Yes
Yes
Yes
Yes
Yes

Bronchitis
Prostatitis
UTI
Pneumonia

1.7
2.8
1.7
1.7

4.3
5.4
4.1
4.0

11
9
6
13

Yes
Yes
Yes
Yes

Cough
Prostrate
cancer

2.6

5.7

17

Yes

3.3

4.9

16

Yes

Bronchitis

2.8, 3.2
2.7, 3.0
1.8
2.5, 3.2
3.1

4.1

4

Yes

4.1
4.2
4.3

3
18
4

Yes
Yes
No

500mg bd x 30 days
500mg x 1 day,
250mg x 4 days
500mg x 1 day,
250mg x 4 days
400mg qd x 19 days
500mg tid x 7 days

Congestion
SOB, cough
Wound care
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Postantibiotic
INR

Days after
starting
antibiotic

Warfarin
held/
reduced

Age
(yrs),
sex

Warfarin
Indication

Antibiotic

Antibiotic Dosage
and Duration

Antibiotic
Indication

Preantibiotic
INR

Postantibiotic
INR

Days after
starting
antibiotic

Warfarin
held/
reduced

83, M

Afib

Moxifloxacin

400mg qd x 9 days

2.7, 2.3

4.2

3

Yes

75, M
82, M
83, M
71, M

Afib
Afib
DVT/ PE
Afib

Moxifloxacin
Amoxicillin
Levofloxacin
Ciprofloxacin

1.7, 2
2.8
2.6
2.7

4.9
4.4
8.0
4.8

3
12
5
20

Yes
Yes
No
Yes

68, M

Afib

Azithromycin

400mg qd x 10 days
875mg bd x 10 days
500mg qd x 7 days
500mg bd x 18 days
500mg x 1 day,
250mg x 4 days

Pneumonia
Pneumonia,
cough, SOB
Cellulitis
Pneumonia
Prostatitis

3.0

4.8

8

Yes

83, M

Azithromycin

2.1

4.3

14

Yes

71, M
77, M
85, M
73, M

DVT/ PE
Cardiomyo
pathy
Afib
Afib
Afib

2.4
2.2, 3.1
2.7, 1.7
3.0, 3.1

4.2
10.8, 6.6
4.1, 4.5
4.3

5
3
3
14

Yes
Yes
Yes
Yes

77, M

Afib

Azithromycin

2.1

4.3

12

No

69, M

AFib

Amoxicillin

2.2, 3.0

5.0

15

Yes

80, M
83, M
	
  

Afib
Afib

Amoxicillin
Moxifloxacin

3.1
2.4

4.3
4.2

4
5

Yes
Yes

	
  

Ciprofloxacin
Amoxicillin
Levofloxacin
Levofloxacin

URI
Mild COPD,
500mg x 1 day,
cough, sore
250mg x 4 days
throat
Prostrate
250mg bd x 14 days biopsy
250 mg tid x 10 days Pneumonia
250 mg qd x 7 days
UTI
500 mg qd x 10 days Epididymitis
250mg bd x 1day;
COPD
qd x 4days
exacerbation
Cold/ sinus
1 tab bd x 20 days
infection
Leg wound
1 tb bd x 7 days
infection
400 mg qd x 14 days Pneumonia
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V. Discussion
The results of this study showed that amoxicillin, azithromycin and fluoroquinolone antibiotics
such as ciprofloxacin, levofloxacin and moxifloxacin, lead to a significant increase in INR values
post-antibiotic use in older patients, when taken concomitantly with warfarin. This increase in
post-antibiotic INR did not lead to clinically significant outcomes of bleeding or hospitalization.
However, warfarin dose adjustments due to an increase in post-antibiotic INR was required for
approximately 20% of patients across the 3 groups of fluoroquinolone antibiotics. In addition,
patients experienced other outcomes of over-anticoagulation such as increase in INR above
therapeutic range and increase in INR by more than 1 point while taking fluoroquinolones and
azithromycin concomitantly with warfarin. Details of patients with an INR ≥ 4 after start of the
antibiotic have been included and almost all these patients had their warfarin dose withheld or
reduced, which may have further prevented any bleeding outcomes. However, these were
patients at a high risk of a hemorrhage, since the risk of serious hemorrhage increases at INR ≥
4.(21) Furthermore, patients taking fluoroquinolones with an indication for skin and soft tissue
infections did not experience an increase in post-antibiotic INR, whereas patients with lower
respiratory infections and urinary tract infections did experience an increase in INR with
fluoroquinolones. These results suggest that type of infection may play a role in the increase in
patient’s INR. A similar conclusion was made in a previous study, wherein the infection, or its
sequelae (i.e. fever and reduced vitamin K intake and uptake) was suggested to increase the
bleeding risk in patients receiving an anti-infective agent, since the ‘baseline’ bleeding risk for
the patients was already elevated even before starting the anti-infective agent.(22)
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Previously, four retrospective cohort studies have assessed the mean change in INR after
administration of levofloxacin to patients on stable warfarin therapy, from which two studies
found a significant increase in mean INR change,(23, 24) whereas the other two studies did
not.(14, 16) There have been only three retrospective studies that have looked at the potential
interaction between azithromycin and warfarin,(15, 17, 24)and two of these did not find any
evidence for a significant interaction between warfarin and azithromycin.(17, 25) The sample
size of these studies was limited with the largest study having a sample size of only 52 patients.
Thus the power to detect a difference in the INR may have been low for most of the studies. The
only study to have assessed the risk of bleeding with amoxicillin for patients on warfarin did not
find an association between risk of hemorrhage and use of warfarin-amoxicillin or warfarinampicillin combination. (26)

Some strengths of this study may be noted. The mean age of patients that were included in this
study was about 76 years. Thus the effect of warfarin-antibiotic interactions could be studied in
older patients. This is important because the older population may be at higher risk of a drug
interaction due to increased sensitivity in pharmacodynamic response to warfarin and reduced
clearance of certain antibiotics such as fluoroquinolones.(6, 27) This was the only known study
to have evaluated the effect on INR values separately for the lower and upper age quartiles. An
age effect was seen such that patients aged ≥ 81 years had a significantly higher mean postantibiotic INR value as compared to patients in the lower age quartile. However, this comparison
was based on fewer observations at the second post-antibiotic INR values. The internal validity
of the study was enhanced by only including those patients who were on stable warfarin therapy
before starting the antibiotic. Thus any increase in INR value after starting the antibiotic may
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become apparent in such patients. Anticoagulation clinic notes made by the Veterans Affairs
clinical pharmacists increases the validity of the findings since the possible reasons for a
supratherapeutic INR are often recorded in the clinical notes. If the clinical pharmacist suspected
that the supratherapeutic INR might be due to the antibiotic this would be noted and would thus
corroborate the findings of this study. However, there may be a systematic reporting bias in this
situation depending on the clinical pharmacist’s beliefs regarding the significance of the potential
drug interaction. Due to this reason clinic notes were only regarded as providing additional but
not definitive evidence. In addition, most patients receive almost all their health care at the VA
and information on concomitant medications, dosage changes, coexisting disease conditions and
health-care procedures is well documented in the patient’s electronic medical record. This
provides additional information on potential confounding factors, unlike large population-level,
health care databases.

There were some limitations of this study given the retrospective nature of data collection.
Changes in use of over-the-counter medications, herbal remedies and other vitamin supplements
with a potential to interact with warfarin may not have been recorded in the patient’s medical
records. Although dietary changes, medication changes and compliance with warfarin therapy
are assessed during each patient visit, patient recall bias may be a potential limitation. For
example, cranberry juice, which is recommended for the treatment of UTIs, may also interact
with warfarin and its use may not be recorded for all patients. However, attempts to control for
potential confounding factors such as use of warfarin interacting medications, fluctuating INR
values, and patient noncompliance were made in the study design by excluding patients with
these factors. Since the data for the study were obtained from an anticoagulation clinic at a
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Veteran’s Affairs Medical Center, only antibiotics on the VA formulary were included. The
results of this study are only generalizable to patients receiving routine monitoring in an
anticoagulation clinic as compared to other models of anticoagulant care. Since warfarin dosage
adjustments were done for patients with supratherapeutic INR values, it was not possible to
ascertain whether supratherapeutic INR would have resulted in clinically significant outcomes of
bleeding or hospitalization through this study. In a setting where patients are not as closely
monitored, the outcomes of bleeding events may vary.

Another possible limitation of the study is that several patients had only one pre- and postantibiotic INR value recorded. The presence of two or more pre- and post-antibiotic INR values
for all patients would have further enhanced the internal validity of the study. However, the
method of analysis chosen for this study was a repeated-effects mixed model ANOVA that does
allow for missing data. In addition, the missing INR values were only for the pre-antibiotic INR
1 values and for the last post-antibiotic INR 2 values, whereas the comparisons were only made
from pre-antibiotic INR 2 to post-antibiotic INR 1. The time points at which pre- and postantibiotic INR values were recorded were not the same for all patients. For example, some
patients may have a pre-antibiotic INR value recorded 10 days before starting the antibiotic and
another patient may have a value recorded 2 days before starting the antibiotic. This may not be a
major limitation since the sole purpose of recording pre-antibiotic INR values was to determine
whether the patient was on stable warfarin therapy. However, post-antibiotic INR values were
recorded within the pre-defined time frame of total duration of antibiotic use plus 14 days after
completing the course of antibiotics. This time frame may have resulted in missing the drug
interaction for some patients. As an attempt to increase the internal validity of the study, only
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those patients on stable warfarin therapy before start of the antibiotic were included. Thus the
results are not generalizable to those patients who may have fluctuating INR values or warfarin
dosage adjustments being made before start of an antibiotic, as may be routinely seen in clinical
practice. Finally, the aim of the study was to characterize warfarin-antibiotic interactions in older
patients and a majority of the patients were white males, thus the results may not be entirely
applicable to other patient populations. This may not be a big issue given that there have been no
reports of gender differences in warfarin PK or PD. However, the prevalence of genetic
polymorphisms for the enzymes that metabolize warfarin is higher in the non-white race and this
may potentially have an effect on warfarin sensitivity in the non-white race. Due to the underrepresentation of the non-white race we were unable to study this effect.

VI. Conclusion
The results of this study provide evidence for an increase in patient’s INR post-antibiotic use that
may lead to a warfarin dose adjustment in several patients, however there was no evidence for
clinical outcomes of bleeding or hospitalization as a result of this increase in INR. These
clinically significant outcomes of bleeding and hospitalization may have been prevented due to
warfarin doses being held or reduced. Based on the results of this study a change in clinical
practice such as empirical reduction of warfarin dose when antibiotics are prescribed
concomitantly with warfarin may not be required. However, the results of bleeding outcomes
may be different in a setting where patients are not monitored as closely as those in an outpatient
anticoagulation clinic. Thus antibiotics may be prescribed to older adults on warfarin therapy as
long as their INR is closely monitored, especially with fluoroquinolones, both during and after
the course of antibiotic therapy.
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CHAPTER 5
DISCUSSION AND CONCLUSION

I.

Underuse of Warfarin in Nursing Home Residents

The results of this cross-sectional analysis of a large nationally representative survey dataset
showed that 54% of nursing home residents with atrial fibrillation, who had indications for
warfarin use and no contraindications to warfarin use, did not receive anticoagulation therapy
with either warfarin or antiplatelet agents such as aspirin or clopidogrel. The next few sections
will outline possible reasons for the observed underuse of warfarin therapy with a focus on
common barriers to warfarin use, barriers to successful implementation of evidence-based
medicine in long-term care settings and tools that may be employed to evaluate risks and benefits
of warfarin therapy in order to assist healthcare providers to identify ‘ideal’ candidates for
anticoagulant therapy.

A. Possible Explanations and Barriers to Prescribing Warfarin
The rate of warfarin use observed in this study was found to be similar to the rates reported
previously.(1-3) It was surprising to find that more than half the NH residents were not receiving
suitable anticoagulation therapy even after excluding those with contraindications to warfarin use
and those without indications to warfarin use. Even though some patients may have
characteristics that would require them to be on an anticoagulant, other reasons such as patient
refusal, patient noncompliance, an upcoming planned surgery and reduced life expectancy may
result in the patient not receiving a prescription for an anticoagulant. In addition, there exist
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several barriers to prescribing warfarin therapy, especially in older adults. The most commonly
cited reason among physicians for not prescribing warfarin is the higher perceived risk of
bleeding associated with warfarin.(4, 5) Increasing age has also been consistently identified as a
barrier to anticoagulant therapy.(6) This was supported by one of the findings of this study,
wherein residents aged 90 years or above were less likely to be prescribed warfarin. However,
the older population is believed to have the greatest absolute reduction in stroke rates with
warfarin therapy.(7) In addition, the prevalence of atrial fibrillation increases with advancing age
such that atrial fibrillation was present in 6% of those aged 65-74 years, 12% in people aged 7584 and 16% in people aged 85 and over.(8) Other factors cited by physicians as challenges to
managing warfarin therapy include, dealing with medications that interact with warfarin,
maintaining patients within therapeutic range and making warfarin dose adjustments.(9) Risk of
falls and dementia are also concerns physicians may have before initiating warfarin therapy.(10).
Lack of reimbursement, time, facilities and/or expertise may be other possible reasons for which
individual practitioners may not be willing to undertake anticoagulation monitoring.(11)
Understanding barriers pertaining to warfarin use in NH residents is important since this would
help to develop targeted interventions to address the issues of underuse of warfarin and other
anti-platelet agents.

Pharmacists-managed anticoagulation services have been shown to improve anticoagulation
control, reduce bleeding and thromboembolic events and reduce rates of anticoagulation-related
emergency department visits.(12, 13) Thus if lack of monitoring or poor monitoring of
anticoagulant therapy in NH residents is a concern, the implementation of pharmacist-managed
anticoagulation services in NHs may be a potential solution towards improving low rates of
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warfarin use in this population. A study that evaluated physician attitudes towards use of
anticoagulation services in NHs found that only about half the physicians surveyed were open to
the idea of an anticoagulation service for their LTC residents.(9) One of the biggest concerns
with use of such services was the potential increase in the cost of care for NH residents on
warfarin. Thus future research may be done to evaluate the usefulness of anticoagulation services
in LTC settings in reducing bleeding and thromboembolic events and cost-effectiveness of
implementing such services.

B. Barriers to Successful Implementation of Evidence-based Medicine in LTC setting
Robust evidence exists for the use of anticoagulant or antiplatelet therapy as stroke prevention
strategies in patients with atrial fibrillation.(14-16) Use of warfarin and other medications such
as aspirin for secondary stroke prevention, have been shown to cause significant reductions in
thromboembolic complications and significant reductions in morbidity and death.(17, 18) Due to
the higher mean age and presence of several cardiovascular conditions that are considered to be
risk factors for a stroke event, the NH population would seem to benefit the most from
anticoagulant therapy for stroke prevention. However, the results of the study outlined in chapter
3, show that a majority of NH residents with atrial fibrillation, with indications for warfarin use
and without contraindications to warfarin, are not receiving anticoagulant therapy with either
warfarin or with anti-platelet agents such as aspirin, clopidogrel or a combination of these
medications. Thus the issue of importance here is the lack of use of evidence-based medicine for
stroke prevention in NH residents. Several barriers to the successful implementation of evidencebased medicine in long-term care residents have been identified previously.(19) For example,
developing evidence-based guidelines for NH residents is a challenge due to the few trials that
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include adults over 80 years of age. The evidence base for clinical management of frail nursing
home residents with AF is limited in terms of risk-benefits with warfarin vs. aspirin and
clopidogrel, since the mean age of patients in the ACTIVE-W trial was 70 years.(20) In addition,
the decision to initiate a medication in a NH resident is not just dependent on the physician, but
also on the patient, the residential care staff and the patient’s next of kin. While it is believed that
NH residents may represent a ‘captive’ audience in a setting where close monitoring by trained
clinical staff is possible on a daily basis and low-cost treatment options exists,(21) it is also
important to note that the rates of staff attrition are very high in NHs.(22) This may further be
complicated by multiple attending physicians, communication difficulties between physicians,
the nursing staff and caregivers and physician visits that are only around once a month.(19) Since
the day-to-day monitoring of residents is often dependent on caregivers and nurses, interventions
to improve prescribing practices targeted solely towards physicians may not always suffice.(19)

C. Evaluating Benefits and Risks to Warfarin Therapy in Oder Adults
According to Quilliam and Lapane ‘non-treatment is not synonymous with under-treatment’.(23)
This is because contraindications to warfarin may influence the decision to treat the patient.
However, in our study patients with contraindications to warfarin use were not included.
Furthermore, contraindications to warfarin therapy may not solely explain the high rates of
underuse observed. Uncertainty regarding treatment risks and benefits may also contribute to the
decision not to treat.(24) This sort of an uncertainty may be due to several factors. For example,
the number and complexity of comorbid conditions, risks of drug interactions and adverse drug
events with concomitant medications, frailty and higher risk of falls and dementia in NH
residents may all be contributing to the uncertainty regarding the decision to treat with warfarin.
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According to the Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA),(25)
and a meta-analysis,(26) the risk of bleeding with warfarin in older patients is no greater than
that with aspirin. With advancing age, aspirin became progressively less effective and instead the
risk of bleeding was found to increase.(26) Thus for patients older than 75 years, formal
anticoagulation with warfarin may remain a preferred treatment option over aspirin.
One way to determine whether an older patient is an appropriate candidate for anticoagulant
therapy would be to evaluate the benefits and risks to warfarin therapy. This may be done
through the combined use of clinical prediction rules for stroke and bleeding risk schemes in
order to identify patients with atrial fibrillation who are likely to benefit from anticoagulant
therapy and less likely to experience an adverse bleeding outcome. A patient’s stroke risk may be
quantified by using one of the many available stroke risk stratification schemes such as
CHADS2,(27) Framingham,(28) NICE guidelines,(29) ACC/AHA/ESC guidelines,(16) ACCP
guidelines,(30) CHA2DS2-VASc(31) and the Rietbrock modified CHADS2 scheme.(32) A recent
study that conducted a comprehensive assessment of these seven stroke risk stratification
schemes in older people with atrial fibrillation, has demonstrated limited ability of these risk
schemes to accurately predict stroke in older people.(33) The CHADS2 and CHA2DS2-VASc
scores performed the best, yet only had a C statistic of 0.60 for their predictive ability. Based on
these results the authors made a pragmatic recommendation for clinicians to classify all patients
over 75 years as being at a high stroke risk and provide them with anticoagulant therapy until
better tools are available for older adults. Meanwhile these risk scores may be used in those
under 75 years.
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Several bleeding prediction models are available to estimate the risk for major bleeding during
anticoagulation therapy. Three bleeding risk schemes that have been developed and validated to
quantify the bleeding risk in patients with atrial fibrillation are known as the Outpatient Bleeding
Risk Index (OBRI),(34) HEMORR2HAGES score,(35) and the more recently developed HASBLED score.(36) Since perceived risk of bleeding may be contributing to underuse of
anticoagulant therapy, use of these bleeding prediction models to quantify the patient’s bleeding
risk may aid in patient selection for anticoagulant therapy. Furthermore, benefits and risks should
be evaluated taking patient preferences into consideration. Even if the decision to initiate
warfarin therapy has been made after careful evaluation of risks and benefits in an individual
patient, the importance of routinely monitoring warfarin therapy can never be replaced.

II.

Warfarin-Antibiotic Interactions

The results of the warfarin-antibiotic research study in this dissertation suggested that there is an
increase in the patient’s INR value as a result of concomitant use of warfarin with antibiotics
such as amoxicillin, azithromycin and fluoroquinolones, such as ciprofloxacin, levofloxacin and
moxifloxacin. This increase in INR did not lead to clinically significant outcomes such as
bleeding and hospitalization, but patients did experience an increase in outcomes of overanticoagulation, such as INR values outside the therapeutic range. The implications of the study
results are that empirical reduction of warfarin dose may not be required when these antibiotics
are prescribed concomitantly with warfarin; however, it would be advisable to closely monitor
patients during concomitant use of warfarin and antibiotics, and to adjust the warfarin dose as
required. Healthcare providers may also need to be aware of this potential interaction between
warfarin and antibiotics, especially in older patients, and the effect that infection or the
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accompanying inflammatory process may have on warfarin metabolism. In the following section
we shall discuss possible explanations for the results of this study and the difficulties with
managing warfarin-drug interactions in older adults.

A. Possible Explanations of Study Results
The primary outcome of change in patient’s INR as a result of warfarin-antibiotic interactions is
an important outcome to consider since the increased risk of hemorrhagic complications as a
result of increasing or fluctuating INR values has been well established previously.(37) Even
though this increase in INR values did not result in bleeding events, the knowledge that
concomitant use of warfarin-antibiotics led to fluctuating INR values is still important since it
may interfere with the routine care and monitoring of patients on warfarin therapy. Maintaining
the patient’s INR between 2.0-3.0 is crucial to attain warfarin efficacy while minimizing the risk
of bleeding. A target INR greater than 3.0 as compared to that between 2.0-3.0, doubles the
frequency of major bleeding events.(38) In addition, anti-coagulated patients, regardless of INR,
are still at bleeding risk. Furthermore, warfarin dose adjustments made by the clinical
pharmacists at the VA anticoagulation clinic, as a result of supratherapeutic INR values, may
have resulted in prevention of bleeding events.

The effect that the underlying infection may have on warfarin-antibiotic interactions is also an
important factor to consider. Cephalexin was the only antibiotic that did not lead to a significant
increase in the patient’s INR post-antibiotic use in this study. One possible reason for this may
be that majority of the patient’s that were prescribed cephalexin had an indication for a skin or
soft tissue infection. During a respiratory infection such pneumonia, there tends to be
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accompanying sequelae such as fever and reduced vitamin K intake, which may increase the
severity of the respiratory infection. However, during a skin infection this is rarely the case.
While a formal analysis for the effect of infection was not done in this study, a post-hoc analysis
revealed a trend for the role of infection. There was no significant increase in the patient’s INR
values when fluoroquinolones were prescribed for skin and soft tissue infections, but the increase
in post-antibiotic INR values was significant when fluoroquinolones were prescribed for lower
respiratory infections and urinary tract infections. Another method to evaluate the effect of
infection on patient’s INR while on warfarin therapy would be via a prospective study wherein
infected patients would have to be denied treatment with an antibiotic. Since this is not feasible
or ethical, healthcare providers should be aware of the potential role of infection in warfarin-drug
interactions.

B. Difficulties with Managing Drug Interactions in Older Adults
Since antibiotics are usually prescribed for a short course of therapy, it may be possible that a
patient is on antibiotics without the knowledge of all of their healthcare providers. Although this
may not be a problem at the VA since patients get most of their prescriptions filled at the VA
pharmacy and patients enrolled in the anticoagulation clinic are routinely evaluated for any
additions or changes in drug therapy, patients across all healthcare settings should be encouraged
to inform their provider about all courses of antibiotic therapy.

Another important issue with warfarin management, especially in NH residents, is the problem
of poor information flow. There have been reported cases wherein a telephone call may have
been made to a physician about a resident with a urinary tract infection without noting the use of

	
  

131	
  

warfarin in the resident.(39) This would normally result in an order for an antibiotic that may
interact with warfarin and thus result in an elevated risk of bleeding for the resident. While this
may not be a problem in a healthcare setting such as the VA, where most of the patient’s
healthcare records are available electronically, it may pose a problem for older patients seeing
multiple providers or in a NH setting with a lack of provider-to-provider communication.
Provider-to-provider communication may be improved via alerts in the electronic-health record
(EHR) systems. The success of an EHR-based Warfarin/Antibiotic Rule in reducing overanticoagulation and adverse outcomes has been tested previously in a case study.(40) Currently
there is no decision-support tool in the VA’s electronic recording system to ‘alert’ providers
against the prescription of these antibiotics for patients on warfarin, and based on the results of
this study, there may not be a need to implement such a system for patients who are closely
followed by an anticoagulation clinic.

III. Relationship Between Under-prescribing and Polypharmacy
There may be a possible relationship between under-treatment with medications and
polypharmacy in older adults. In a study of 154 geriatric out-patients, polypharmacy, defined as
the use of 5 or more medications, was present in 61% from which 43% of these patients were
undertreated for a disease for which drug therapy was indicated.(30) In contrast to 43% of
patients with polypharmacy that were under-treated, only 13.5% of patients using 4 or less drugs
were under-treated (adjusted OR = 4.8, 95% CI = 2.0 – 11.2), suggesting that there is a
relationship between polypharmacy and under-treatment. Possible reasons for this relationship
may be that physicians are cautious while prescribing multiple medications to patients on
complex drug regimens due to fear of adverse drug reactions, interactions and poor compliance.
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In this dissertation the issues of underuse of warfarin and warfarin-drug interactions in older
adults were highlighted. Both of these are important issues in older adults and they may also be
related in some way. Warfarin is known to interact with many medications and due to this reason
physicians may be cautious while prescribing warfarin to a patient who already has a complex
medication regimen.

III.

Role of Newly Approved Oral Anticoagulants: Dabigatran and Rivaroxaban

Since warfarin has a narrow therapeutic index, inter-individual variability in dose response,
numerous drug and food interactions, routine monitoring and dose adjustments are required for a
patient on warfarin. Due to these reasons the risk of under-treatment with warfarin is also very
high. As a result of challenges associated with warfarin management several attempts have been
made to develop newer and safer oral anticoagulants. The direct thrombin inhibitor, dabigatran
gained FDA approval for prevention of stroke in patients with AF in September 2010 and the
direct factor Xa inhibitor, rivaroxaban recently gained approval for use in patients with AF in
November 2011, based on their demonstrated efficacy in phase 3 clinical trials towards
prevention of stroke and systemic embolism in patients with AF.(41, 42) In addition to their
recommended use in patients with AF, dabigatran and rivaroxaban have demonstrated efficacy
and safety for use in venous thromboembolism prophylaxis in orthopedic surgery patients.(43) A
lot of emphasis has been placed on the advantages of dabigatran and rivaroxaban in terms of
reduced patient monitoring required, administration at fixed doses and renal excretion of these
medications.(44) However, a point of caution is that the efficacy and safety of these medications
have not been evaluated in patients with renal failure.(44) This may have important implications
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for use in patients with moderate to severe renal insufficiency and especially for the older patient
population that is known to have a decline in renal function. In addition, there is lack of a widely
available antidote to these medications in case of a severe bleeding event or an emergency
situation.(45) Further information is required from post-approval studies regarding the
effectiveness of the newer oral anticoagulants and appropriate monitoring methods in the older
adult population, especially frail nursing home residents. As long as caution is exercised while
prescribing these medications during daily practice, they may still serve as alternate treatment
options for patients with a high-risk profile for stroke but with contraindications to
anticoagulation with warfarin. On the other hand switching a NH resident from stable warfarin
therapy to the newer anticoagulants may not be necessary given the established benefits of
warfarin for stroke prevention and lack of information on use of these newer agents for patients
with mechanical heart values or other indications. Furthermore, in certain situations a monitored
anticoagulant such as warfarin may be preferred. For example, as long as warfarin is not
contraindicated, due to the available methods of monitoring patients on warfarin, it may be a
preferred anticoagulant for NH residents, for older patients with multiple co-morbid conditions
and for patients using multiple medications that have a potential to interact with the
anticoagulant. The ability to monitor the patient in such situations may be a more attractive
option for the healthcare provider.

In terms of drug interactions with the newer anticoagulants, there is limited information about
potentially interacting medications and strategies to manage these interactions. Since dabigatran
is not metabolized by the CYP450 enzyme system, it appears to have the lowest drug interaction
potential, whereas rivaroxaban is partly metabolized by CYP3A4. (46) A recent review article
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has summarized some of the recognized food and drug interactions with the newer oral
anticoagulants,(43) However, the data for most of these drug interactions were obtained from
animal models or healthy subjects, suggesting that there is a lack of clinical experience with new
oral anticoagulants and hence lack of information on clinical significance of drug interactions
with these agents. Furthermore, patients with severe liver and renal diseases were excluded from
the clinical trials of dabigatran and rivaroxaban.(43) Thus due to altered metabolic capacity in
case of hepatic or renal diseases, or for older patients with hepatic or renal function decline, the
pharmacokinetics and pharmacodynamics of new oral anticoagulants may be affected, and as a
result the potential for a drug interaction may be augmented.(43) Due to a lack of reliable
monitoring parameters, management of drug interactions with dabigatran and rivaroxaban may
be further complicated.

V. Conclusions and Future Research
The research underlying this dissertation highlights two important medication-related problems
in older adults, that is, under-treatment and drug-drug interactions, using a high-risk drug such as
warfarin as the example. The first project highlighted the high rates of underuse of warfarin in
nursing home residents with atrial fibrillation along with the factors associated with warfarin use,
such as increasing age, race, stroke and bleeding risk factors. The second project provided
evidence for an increase in anticoagulant activity for warfarin, as measured by the patient’s
international normalized ratio (INR), when antibiotics such as fluoroquinolones, azithromycin
and amoxicillin were used concomitantly. While the currently available research on warfarin
underuse and warfarin-antibiotic interactions has been conducted across the entire adult
population, the research work undertaken in this dissertation represents the evidence for
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underuse and drug interactions specifically for the older adult population, which is the population
that tends to have the highest prevalence of conditions for which warfarin is indicated.

Drug interactions have been designated as a drug safety measure by the Center for Medicare and
Medicaid Services (CMS) and several quality improvement organizations throughout the nation
have invested time and efforts in reducing warfarin-drug interactions, including warfarinantibiotic interactions as part of CMS’s drug safety initiative. Thus warfarin-drug interactions is
a medication-related issue that is given national importance and the results of this study shed
light on the clinical significance of warfarin-antibiotic interactions in the older adult population
from an anticoagulation clinic.

There remains room for future research to determine barriers to anticoagulation prescribing for
NH residents and developing targeted interventions to increase rates of anticoagulation. The role
of newly approved anticoagulants, dabigatran and rivaroxaban, in influencing the patterns of
anticoagulation in NH settings remains to be determined. While warfarin-antibiotics may be
safely prescribed to older adults as long as their INR is being frequently monitored, the safety of
warfarin-antibiotic interactions in other models of anticoagulation care, such as home based care
or the usual care model remains to be ascertained.
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APPENDIX A
List of validated ICD-9 codes used to identify diseases and conditions of
interest
Disease/ conditions of
interest
Atrial fibrillation
Congestive heart failure
Hypertension
Diabetes
Previous stroke/ TIA
Coronary heart disease
Valvular heart disease or
valve replcement
DVT/ arterial peripheral
embolus
Hemorrhagic tendencies
Recent surgery

History of GI bleeding
Dementia
Myocardial infarction
Chronic kidney disease
(CKD) or renal failure (RF)
Cancer (malignancy)

Hepatic (liver disease/
abnormal liver function)

ICD-9 codes
427.31
428, 398, 402, 404
401-405, 437
250
434-436
410-414, 429, V45
394- 398, 424, V42, V43
415, 444, 445, 451, 453
286- 287
Sepsis (038, 020, 790, 117, 112), cardiac catheterization (37),
cardiac surgery [coronary artery bypass graft surgery (36), valve
repair (35)]
531-534, 578
290
410
CKD= 403, 404, 250, 581-583, V42; RF= 584-586, 638, 639,
403, 404
Colon (153), breast (174), lung (162), prostrate (185),
melanoma(172), myeloma (203), kidney (189), bladder (188),
HIV infection (042)
Acute hepatic failure or necrosis (570), hepatic encephalopathy
(573)

TIA= Transient ischemic attack; DVT = Deep vein thrombosis
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APPENDIX B
NAMCS reason for visit (RFV) codes to identify contraindications to warfarin
(according to Coumadin package insert)
Warfarin contraindications
1. Hemorrhagic tendencies or blood
dyscrasias

RFV
code
1640

Description
Abnormalities of urine: blood in urine
(hematuria)
cerebrovascular disease: CVA, cerebral
hemorrhage, stroke
GI bleeding; blood in stool (melena),
vomiting blood
Major surgery

2525
2. Active GI ulceration

1580

3. Recent surgery

4521
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APPENDIX C
List of Long-term Care Drug Database System (LTCDDS) codes used to
determine drug exposure for NH residents with AF
Drug
Warfarin
Aspirin

Clopidogrel
Ticlopidine
Dipyridamole
NSAIDs:
Aspirin
Celecoxib
Diclofenac
Diflunisal
Etodolac
Fenoprofen
Ibuprofen
Indomethacin
Ketoprofen
Meclofenamate
Meloxicam
Nabumetone
Naproxen
Oxaprozin
Piroxicam
Rofecoxib
Salsalate
Sodium
salicylate
Sulindac
Valdecoxib

	
  

LTCDDS codes
07930, 34775
97174 (baby aspirin; 81mg), 10975 (ecotrin; 81mg), 00078 (aggrenox; asprindypyridamole, 20mg/250mg), 00100 (ASA; 325mg), 93245 (halfprin; 81mg
or 162mg)
99033, 98086
93192, 93362
23535, 09920
51380, 00100, 02725, 25520, 23390, 12550, 04194, 21290, 02805, 41880,
01755, 27300, 97174, 10975, 00078, 00100, 93245
99002
02148, 34725, 92116, 98006
10126
92051, 92124
20210
89050, 19675, 15395, 00597, 98043
15590, 15600
93432, 93312, 61100
18558
00048
93132, 94179
04382, 20285, 20290, 01838, 94125
94127, 93399
12193, 92145
01048, 99067
27405, 09925, 27407
93140, 27340
29998, 06935
02014
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APPENDIX D
Description of the Variables Collected from Electronic Medical Records
Variable

Variable Name

Type

Patient number

PT_NO

Discrete

Observation
number

OBS

Discrete

Age

AGE

Sex
Race
Indication for
warfarin use

INR goal
Warfarin
Regimen
Antibiotic
prescribed
Antibiotic start
date
Dose and
duration of
antibiotic use
Indication for
antibiotic use

Pre-antibiotic
INR 1
Date of preantibiotic INR
1
Pre-antibiotic
INR 2

	
  

Description
Unique number assigned by the researcher
to each patient
Number assigned to observations from each
patients

Continuous Exact value in years obtained from the
medical records
SEX
Categorical Male or Female
RACE
Categorical White, African-American or Hispanic
IND
Categorical Indication for which patient was prescribed
warfarin- atrial fibrillation; atrial fibrillation
or atrial flutter; atrial flutter; deep vein
thrombosis or pulmonary embolism;
mechanical value replacement; other
conditions
INR_GOAL
Continuous Recommended INR therapeutic range
WAR_REGIMEN Continuous Daily and weekly warfarin dose recorded
from anticoagulation clinic notes
ANT
Categorical Antibiotic generic name recorded from
outpatient pharmacy prescription record
ANT_START
Date
Date antibiotic was started; verified from
patient medical record
ANT_DOSE_DUR
Antibiotic dose and duration recorded from
Continuous outpatient pharmacy prescription record;
verified from patient medical record
IND_ANT
Categorical Indication for which antibiotic was
prescribed to patient- upper respiratory
infections (URIs); pulmonary infections;
urinary tract infections (UTIs); skin; other
infections
PRE_INR_1
Continuous INR value collected during the 4-week
period before start of antibiotic; exact INR
values as recorded in the clinical notes (if
available)
DATE_1
Date
Date pre-antibiotic INR value was recorded
in clinical notes
PRE_INR_2

Continuous INR value collected during the 4-week
period before start of antibiotic; exact INR
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Variable

Variable Name

Type

Description
values as recorded in the clinical notes
Date pre-antibiotic INR value was recorded
in clinical notes

Date of preantibiotic INR
2
Post-antibiotic
INR 1

DATE_2

Date

POST_INR_1

Date of postantibiotic INR
1
Post-antibiotic
INR 2

DATE_3

Continuous 1st INR value collected during the duration
of use of antibiotic or during the 14-day
period following discontinuation of
antibiotic
Date
Date post-antibiotic INR value was
recorded in clinical notes

Date of postantibiotic INR
2
Number of
concurrent
medications
Number of comorbidities
Warfarin dose
withheld
Warfarin dose
reduced
New warfarin
dose regimen
Minor bleeding
event
Major bleeding
event
Vitamin K
administered
Emergency
department visit

DATE_4

	
  

POST_INR_2

TOTAL_MEDS

Continuous 2nd INR value collected during the duration
of use of antibiotic or during the 14-day
period following discontinuation of
antibiotic (if available)
Date
Date post-antibiotic INR value was
recorded in clinical notes
Continuous Counted number of medications taken by
each patient (from medical records)

TOTAL_COMOR Continuous Number of all co-existing conditions (from
medical records)
WAR_HELD
Categorical ‘Yes’ for warfarin dose withheld or ‘No’ for
dose not withheld
WAR_REDUCED Categorical ‘Yes’ for warfarin dose reduced or ‘No’ for
dose not reduced
WAR_NEW_REG Continuous Change in warfarin dose regimen
MINOR_BLEED
MAJOR_BLEED
VITK_AD
ED_VISIT

Categorical ‘Yes’ for minor bleed or ‘No’ for no minor
bleed
Categorical ‘Yes’ for major bleed or ‘No’ for no minor
bleed
Categorical ‘Yes’ for vitamin K administered or ‘No’
for vitamin K not administered
Categorical ‘Yes’ for patient with emergency
department visit, ‘No’ for no emergency
department visit
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APPENDIX E
SAS codes for Repeated Measures ANOVA
The SAS code
/*****************************************************************************
****************REPEATED MEASURES ANOVA********************/
/********* stacking the INR values ****************/
data Mylib.warfarin_long;
set Mylib.warfarin_1;
inr = pre_inr_1; time = 1; output;
inr = pre_inr_2; time = 2; output;
inr = post_inr_1; time = 3; output;
inr = post_inr_2; time = 4; output;
drop pre_inr_1 pre_inr_2 post_inr_1 post_inr_2;
run;
proc sort data = Mylib.warfarin_long;
by ant;
run;
/*To test for effect of antibiotics on INR values over time, is there an interaction between
antibiotic and time*/
/********** Method 1: Compound Symmetry ****************/
proc mixed data = Mylib.warfarin_long;
class ant time obs;
model inr = ant time ant*time;
repeated time / subject = obs type = cs;
lsmeans time*ant/ diff adjust = tukey cl slice=ant;
title 'antibiotic interaction: CS';
run;
/**************Method 2: Auto-regressive***************/
proc mixed data = mylib.warfarin_long;
class ant time obs;
model inr = ant time ant*time;
repeated time / subject = obs type = ar(1);
lsmeans time*ant/ diff adjust = tukey cl slice=ant;
title 'antibiotic interaction: AR(1)';
run;
/*****************Method 3: Unstructured*************/
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ods trace on;
ods graphics on;
ods output Tests3= Mylib.type3test;
ods output LSmeans=Mylib.means;
ods output Slices=Mylib.slices;
ods output Diffs=Mylib.difference;
proc mixed data = mylib.warfarin_long;
class ant time obs;
model inr = ant time ant*time;
repeated time / subject = obs type = un;
lsmeans time*ant/ diff adjust = tukey cl slice=ant;
title 'antibiotic interaction: UN';
run;
ods graphics off;
ods trace off;
Definition of the variable names in the Proc Mixed code
ant = the type of antibiotic received i.e. amoxicillin, azithromycin, cephalexin,

ciprofloxacin,

levofloxacin, moxifloxacin
time = 4 time periods during which INR values were recorded; first 2 INR values were recorded
pre-antibiotic use, last 2 INR values were recorded post-antibiotic use
obs = patient
Description of the Proc Mixed code
Data = the name of the dataset to be analyzed
Class = the classification variables to be used in the analysis, i.e. the categorical variables are
obs, ant and time.
Model = the statement that specifies the model for the analysis. The first variable, i.e. INR, is the
response variable. Following the ‘=’ are the explanatory variables, i.e. the variables which may
be affecting the INR values. In this study we are looking to see if change in INR values over time
is different for different antibiotics, so an interaction term ant*time is added in the model
statement. Since this interaction term was found to be significant, the results are interpreted
accordingly.
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Repeated = is used to specify the correlation structure of the data. Here there are repeated
measures on each patient. The obs variable uniquely identifies the patients. The repeated
statement is followed by the repeated effect, here time. The subject = obs is used to specify the
subject effect and the type = UN option is used to specify the correlation structure for the
variance-covariance matrix.
All 3 covariance structures (CS, AR(1) and UN) are used and the model with the minimum AIC
values is chosen (UN).
Random = specifies the variable which is causing the random variability within the study, i.e.
obs (patient) in this case. In most analyses, the subject is conceived to be a random representative
of all possible subjects. Year or time is the fixed-effect, that is, its values represent specific levels
of the factor and these values are “fixed” in the sense that out hypotheses refer to comparisons
between these specific levels. Since the final model includes both fixed and random effects, the
model is termed a “mixed model”.
LSmeans = the statistical method used to test the differences in INR values across the time
points and between antibiotics, i.e. comparing the estimated adjusted mean value of the INR
values between the different antibiotics and across the different time points (2 and 3 time points
are of interest for this study).
Ods output = outputs the results of the individual lsmeans to the ‘means’ dataset in the Mylib
folder, and the difference of the lsmeans computed using test slices is outputted to the
‘differences’ dataset in the Mylib folder.
Information obtained from the SAS log
If the model is correct there will be a note in the log ‘Convergence criteria met’. If not, then the
model need to be changed or the assumption of normality of the data is incorrect. In this case the
convergence criteria was met using all 3 covariance structures and the model that gave the
minimum AIC values (i.e. UN) was chosen.
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